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Most standard AML chemotherapy regimes utilize Ara-C, a cytotoxic compound 
inflicting DNA damage in proliferating cells and inducing cell death. Comparing 
normal and malignant haematopoietic cells in their response to Ara-C will 
determine whether differing responses to DNA damage and activation of DNA 
repair mechanisms contribute to chemoresistance. Moreover, DNA repair in 
primitive human haematopoiesis and LIC’s is still not well established.  
 
Using AML cell lines, cord blood and CD34+ AML patient samples, a 
characterization of the DNA damage response post Ara-C treatment was 
performed. AML cell lines were shown to have a range of sensitivities with 
significant increases in DNA damage after Ara-C exposure. However, cell lines 
resistant to Ara-C, were quicker to recover their DNA damage, with a faster revival 
of cell numbers and reduction in apoptosis. Similar findings were also observed 
when using ionizing radiation as a source of DNA damage. Analysis of the DNA 
repair mechanisms non-homologous end joining (NHEJ) and homologous 
recombination (HR) by 53BP1 and RAD51 localization respectively, showed NHEJ 
was preferentially used in response to Ara-C, with low rates of HR.  
 
Normal haematopoietic stem and progenitor populations were compared with 
leukaemia initiating and tumour populations of CD34+ AML patient samples in vivo.  
Normal stem populations showed significant increases in apoptosis with 
enrichment in cells in G0 after exposure to Ara-C. Progenitor cells were more 
refractory to treatment and displayed a G1/S-phase accumulation. When observing 
AML patient samples it appeared they either behaved in a progenitor, or a stem like 
manner, showing heterogeneous responses overall. Just like the AML cell lines 
NHEJ was primarily observed, with some basal level of activation. Overall there are 
differences in normal stem progenitor and cells in response to Ara-C, with AML 
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Chapter 1. Introduction 
1.1 Normal Haematopoiesis 
Within the mammalian body, blood is one of the most highly regenerated tissues 
with ~10 billion of new cells being produced on a daily basis in a human adult. For 
systems with such high cellular turnover, stem cells and their self-renewal 
properties are paramount to the on-going regeneration, maintenance and function 
of their resulting organs. The haematopoietic system is one of the most established 
and researched adult stem cell hierarchies. It was over a century ago that biologists 
began to hypothesise that all blood lineages were organised in a hierarchical 
nature deriving from a common precursor, which would be coined the 
haematopoietic stem cell (HSC) (Maximow, 1909). However definitive proof of the 
existence of such a blood stem cell wouldn’t be discovered until decades later 
when the more advanced methods available showed that HSC’s had multi-lineage 
potential using in vivo repopulation assays (Becker et al., 1963, Till and McCulloch, 
1961). These seminal studies opened the gateway into the study and 
characterisation of the haematopoietic hierarchy, which places the HSC at the apex 
and mature terminally differentiated erythrocytes, lymphoid cells and myeloid cells 
at the ends of the hierarchy branches (Eaves, 2015). 
 
Significant breakthroughs in the architecture of the haematopoietic system and its 
regulation would not have been possible without vertebrate models, such as 
zebrafish and the mouse. Knowledge gained from these animal studies has been 
translated to better aid our understanding of the human system, where 
understandably direct human experimentation cannot be performed. It has only 
been through clinical observations and major technological advances with in vitro 
assays and in vivo xenograft models where huge progress has been made in the 
ability to directly study human haematopoiesis (Doulatov et al., 2012). 
 
1.1.1 Haematopoietic Hierarchy 
At the top of the haematopoietic hierarchy lays the long-term HSC (LT-HSC). This 
precious reservoir of cells is retained throughout the lifetime of the individual and is 
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largely quiescent.  However, to create the full haematopoietic system, while 
maintaining their own numbers, LT-HSC must divide asymmetrically and self-renew. 
Thus this creates new pools of differentiated progeny termed the short-term HSC 
(ST-HSC) and multipotent progenitors (MPP). These populations have decreased 
self-renewal ability and higher proliferative capacity compared to the LT-HSC, 
allowing the LT-HSC to maintain its integrity. This means the ST-HSC/MPP’s are 
the real powerhouses of the haematopoietic system, as they retain multi-potency 
and can give rise to abundant numbers of differentiated oligopotent progenitors. 
 
To be able to accurately replenish the high turnover of erythrocytes and balance 
the amount of myeloid and lymphoid cells in the bone marrow and periphery, the 
hierarchy needs to be a tightly regulated homeostatic process. This relies on very 
specific cell autonomous and environmental queues where during times of stress, 
such as infection or bleeding, the haematopoietic system must be able to quickly 
and accurately mount an appropriate response. This may require producing more 
of a certain mature blood cell to ensure homeostasis is maintained. Therefore, the 
hierarchical nature of the blood system is a robust and efficient way to ensure 
regeneration while protecting the valuable pool of HSC’s. 
 
1.1.2 Haematopoietic stem cells 
HSC are typically identified from other haematopoietic cells by the expression of 
certain immunogenic surface markers and by their functional capacity to self-renew 
and reconstitute multiple mature blood lineages. Although much progress has been 
made in the ability to directly study human haematopoiesis, many questions can 
still only be feasibly answered by examining the murine haematopoietic system. 
This means the need for in depth characterisation of the murine LT-HSC and 
resulting progeny. Mature populations are first excluded based on a combination of 
surface markers exclusively expressed on lineage-committed cells. The resulting 
lineage negative cells can be further purified for functional HSC’s by expression of 
Sca-1 (Stem cells antigen-1) (Spangrude et al., 1988) and c-Kit (receptor tyrosine 
kinase; CD117) (Morrison and Weissman, 1994). Known as the LSK population, 
this is a mixture of LT-HSC, ST-HSC and MPPs with heterogeneous self-renewal 
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ability where 100 cells have been shown to have long-term repopulating ability in 
lethally irradiated murine hosts (Okada et al., 1992). Further enrichment for more 
purified stem populations were later characterised by negative expression of CD34 
and Flt3 (Fms-like receptor tyrosine kinase 3; CD135) (LSK-CD34-Flt3-) (Osawa et 
al., 1996, Adolfsson et al., 2001, Yang et al., 2005). However, more recently an 
alternative way using antigens from the Slam family of markers, CD48 and CD150 
(LSK-CD150+CD48-), has produced functionally similar populations of LT-HSC (Kiel 
et al., 2005). 
 
Although characterisation of the human LT-HSC has been challenging due to 
experimental limitations, there has been great success over the decades in refining 
a highly purified stem population. Key to this has been the use of the xenograft 
model and the development of fluorescence activated cell sorting (FACS) 
technologies. This relies on the transplantation of populations of human 
haematopoietic cells in limiting dilution, which have been purified by FACS based 
on surface marker expression, to help assess multi-lineage repopulating ability. 
One of the first widely accepted molecules for identification of immature 
haematopoietic cells was the CD34 antigen (Civin et al., 1984). Although its exact 
function has not been fully elucidated it is believed to be involved in cell-cell 
adhesion and attachment to the bone extracellular matrix (Nielsen and McNagny, 
2009). CD34+ cells make up a mixture of haematopoietic stem and progenitor cells 
(HSPC), which constitute 1-4% of bone marrow mononuclear cells (MNC) (Civin et 
al., 1984) and approximately 2% of umbilical cord blood (UCB) (Fritsch et al., 1996). 
Primitive populations were further defined by discovery of the CD90 (Thy-1) antigen, 
where Lin-CD34+CD90+ cells were able to repopulate SCID mice with both 
myeloid and lymphoid lineage engraftment (Baum, 1993). Additional refinement 
was also attained by the negative selection of the CD38 glycoprotein (Bhatia et al., 
1997) and CD45RA markers (Lansdorp et al., 1990). 
 
Hence, the human HSC was primarily identified as Lin-CD34+CD38-
CD90+CD45RA-, with Majeti et al., showing long-term multi-lineage engraftment in 
a third of NSG (non-obese diabetic (NOD)-severe combined immunodeficient (scid) 
IL2rγ (null)) mice engrafted with as little as 10 cells (Majeti et al., 2007b). It was 
anticipated that the loss of CD90 would characterise the more differentiated MPP, 
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however CD34+CD90- cells were still able to serially transplant, even if diminished 
in their ability compared to the CD90+ HSCs (Majeti et al., 2007b). This led the 
need to find the closest progeny to the HSC where self-renewal was properly 
diminished, based on something further than negative and positive CD90 
expression. Integrin’s were a prime candidate as it had already been shown in the 
murine HSC that expression of integrin α2 (CD49b) allowed the differentiation 
between ST-HSC and LT-HSC (Benveniste et al., 2010). This led to the discovery 
that integrin α6 (CD49f) surface marker expression, on purified human single cells 
injected intra-bone, were able to engraft long-term with multi-lineage output with 
successful secondary transplantation (Notta et al., 2011). Therefore overall, it’s 
widely accepted that Lin-CD34+CD38-CD90+CD45RA-CD49f+ defines a very pure 
human LT-HSC population. 
 
Recent studies have provided evidence for another layer on top of the human 
hierarchy, beyond a CD34+ stem cell, which reflects the murine CD34- HSC. 
CD34- cells purified from UCB were shown to give rise to CD34+ cells and multi-
lineage engraftments when injected intra-bone into SCID mice (Ishii et al., 2011). 
Attempts to find additional surface markers for better identification of these cells 
uncovered expression of CD93 or CD133 (promonin-1) as good candidates for 
further purification (Takahashi et al., 2014, Danet et al., 2002). As well, using serial 
transplantation assays, they appear to possess greater self-renewal capacity than 
CD34+ HSC. Evidence suggests these cells are able to differentiate into CD34+ 
cells providing a strong case for an additional layer at the top of the haematopoietic 
hierarchy (Anjos-Afonso et al., 2013). 




Figure 1.1 The human and murine haematopoietic hierarchy.  
 
1.1.3 Multi-potent progenitors 
Directly beyond the HSC in the hierarchy lies the MPP, which are characterised 
with decreased self-renewal but retention of full differentiation capacity. In the 
mouse this was defined as the CD34+Flt3+LSK population, which retains multi-
potency but with reduction in self-renewal capacity (Adolfsson et al., 2001). This 
helped support the idea that decreasing self-renewal gives way to increasing 
lineage commitment. However, efforts over the last few years have further defined 
the murine MPP into functionally different subpopulations.  It was observed 
previously that in LSK, high expression of Flt3+ outlined cells that were still 
multipotent but possessed lymphoid bias (Adolfsson et al., 2005). These were 
dubbed lymphoid-primed MPP (LMPP), only to be renamed a couple of years later 
to MPP4 when evidence of myeloid biased subpopulations MPP2 (Flt3-
CD150+CD48+LSK) and MPP3 (Flt3-CD150-CD48+LSK) emerged, primarily 
distinguished by their negative expression of Flt3 (Wilson et al., 2008). In this 
analogy MPP1 refers to a metabolically active murine HSC, unlike the quiescent 
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CD34- HSC (Cabezas-Wallscheid et al., 2014). In depth functionality studies 
comparing the different MPPs, by individually transplanting each population, 
showed each was produced independently by the HSC and gave rise to multi-
potent engraftment up to 4 weeks (Pietras et al., 2015). Yet the different MPP were 
biased, as respectively described before, in their generation of mature cells.  
 
In the human system the MPP population was previously distinguished as Lin-
CD34+CD38-CD45RA-CD90-CD49f- and when transplanted into NSG mice, gave 
a transient short-term multi-potent engraftment, which peaked at 4 weeks and 
became indiscernible by 16 weeks (Majeti et al., 2007a). Again, this reflected that 
the MPP could be defined as having multi-potent potential yet reduced self-renewal 
compared to the HSC. More recently they were sub-fractionated, based on the 
expression of CD71 (Transferrin receptor) and CD110 (Thrombopoietin receptor), 
into MPP F1, F2 and F3 (Notta et al., 2016). Just like the murine MPP populations, 
these were shown to display early lineage bias with F1 able to give rise to 
predominantly megakaryocytes and F2/F3 cells being more biased towards 
erythroid lineages. A comparison of these populations was undertaken through 
different development stages of haematopoiesis by analysing foetal liver (FL), CB 
and adult BM. It could be seen that there was a fundamental developmental shift as 
FL presented more oligopotent progenitors whereas the adult BM held primarily 
unipotent progenitors, appearing to come directly from MPPs. This could potentially 
redefine adult haematopoiesis as being a ‘two-tier’ system, unlike the current 
widely accepted model of a hierarchy with progressively differentiated populations 
(Figure 2).  




Figure 1.2 Redefined model of human haematopoiesis. 
The current still widely accepted model of haematopoiesis states that cells mature 
through a number of differentiation stages, with intermediate progenitor cells, which 
progressively lose potency to eventually reach mature unipotent haematopoietic cells. 
However Notta et al., showed that in adult bone marrow unipotent cells can arise 
directly from multipotent progeny, suggesting the oligopotent step in between is not 




Downstream of the MPPs lies the lineage restricted progenitors that reside in the 
Lin-CD34+CD38+ fraction of human CB and bone marrow. The CD45RA and 
CD123 (IL-3Rα) surface markers can primarily define the myeloid hierarchy into the 
common myeloid progenitor (CMP), which gives rise to the 
granulocyte/macrophage progenitors (GMP), and in turn differentiates into the 
megakaryocyte/erythrocyte progenitors (MEPs). These progenitors allow the 
production of granulocytes, dendritic cells, monocytes (GMP), megakaryocytes and 
erythrocytes (MEP) (Manz et al., 2002).  
 
The standard human hierarchical model states that the separation of myeloid and 
lymphoid lineages occurs at the split between CMP and the common lymphoid 
progenitor (CLP), creating the first lineage commitment step. As described in the 
previous section, this is now under dispute with evidence of early lineage biasing 
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taking place before differentiation into lineage commitment. A multi-lymphoid 
progenitor (MLP) population, described as CD34+CD38-CD90-CD45RA+CD10+, 
gave rise to all lymphoid lineages and possessed some myeloid potential, but no 
erythroid or granulocytic segregation (Doulatov et al., 2010). As well, in comparison 
to the murine LMPP, a human counterpart in UCB was described as CD34+CD38-
CD45RA+CD10-, which had the added ability to produce granulocytes compared to 
the MLP (Goardon et al., 2011a). This showed that expression of CD10+ was 
required for lymphoid differentiation whereas CD10- cells were chiefly myeloid. 
However, these studies were preformed using UCB and analysis of adult BM 
showed that the LMPP population is actually within the CD38+ fraction and 
expresses high levels of CD62L (L-selectin) (Kohn et al., 2012). Work by 
Yamamoto et al has even described a “myeloid bypass model’ wherein the murine 
HSC can asymmetrically divide to directly produce a fully lineage committed 
myeloid precursor with long-term repopulating ability (Yamamoto et al., 2013). 
Evidently there’s not a clear-cut delineation between myeloid and lymphoid 
commitment as previously thought. 
 
1.1.5 In vivo Assays – Xenograft Model 
As eluded too in previous sections, use of the xenograft model has been 
paramount in the study of human haematopoiesis. The expression of certain panels 
of surface markers on haematopoietic cells does not guarantee they behave in a 
homogenous manner, meaning functionality must be tested by assessing long-term 
and multi-lineage engraftment potential of purified cells injected into 
immunodeficient mice. 
Success of the xenograft model relies on three key principles: 
1. The recipient mouse must be sufficiently immune deficient to reduce the 
possibility of graft rejection. 
2. There must be a suitable niche for accommodation of human cells. 
3. The niche must be able to support the human haematopoietic cells over a 
long period of time. 
One of the first widely used models was the server combined immunodeficient 
(SCID) mouse, which lack T and B lymphocytes, and must to be irradiated pre-
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engraftment to clear the bone marrow of murine cells and provide niche spaces for 
human HSC (McCune et al., 1988). This model however requires larges numbers 
of donor cells to be injected and still holds an innate immune system, with presence 
of natural killer (NK) cells and macrophages impeding engraftment. 
 
To solve the problem of residual macrophages, the SCID model was crossed with 
mice on the non-obese diabetic (NOD) background, providing immune deficient 
mice whose macrophages can tolerate human material (Pflumio et al., 1996). 
Irradiated NOD/SCID mice permit the engraftment of small numbers of human 
CD34+ cells and are able to reconstitute a multi-lineage engraftment (Shultz et al., 
2005). 
 
Nevertheless, the NOD/SCID model does not come without its caveats. With a high 
occurrence of thymic lymphoma and the prevalence of natural killer (NK) cells, 
long-term engraftment studies were a struggle to perform (Prochazka et al., 1992). 
To achieve disruption of NK cells, the IL-2 receptor common gamma chain (IL-2Rγ) 
was deleted to interfere with cytokine signalling downstream of IL-15, a crucial 
cytokine needed for NK development (Ito et al., 2002). This resulted in the 
NOD/SCID/ IL-2Rγnull (NSG) model, devoid of B, T and NK cells with tolerant 
macrophages, which is now one of the most commonly used models for xenograft 
studies. 
 
Additionally, attempts to humanize the mouse, ensuring sufficient homing, 
maintenance and differentiation of the human HSC, have been undertaken. 
Expression of the human cytokines thrombopoietin (TPO); IL-3; granulocyte-
macrophage colony stimulating factor (GM-CSF) and stem cell factor (SCF) have 
all been achieved in the murine system (Chen et al., 2009). They help create a 
more hospitable environment, by creating a deficiency in the murine cytokines thus 
causing impairment of the host HSC and macrophages (Willinger et al., 2011).  
 
All these improvements have helped the maintenance and differentiation of human 
HSPC post engraftment and have been so far invaluable in the study of human 
haematopoiesis. However, the xenograft models still do not come without their 
limitations. While primitive populations are well recapitulated in NOD/SCID and 
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NSG mice, the differentiation into mature lineages is largely impaired. Development 
of functional myeloid and NK cells is limited with a bias towards production of 
lymphoid B cells, which is not reflective of the human situation (Manz, 2007). The 
NSG-SGM3 model, which expresses SCF, GM-CSF and IL-3, was specifically 
designed to aid the engraftment and support of myeloid/lymphoid cells. Although 
this provides higher engraftment levels, it comes at the expense of early exhaustion 
of the HSC (Nicolini et al., 2004).  This leads to another drawback in delineating the 
appropriate time-point to assess the end-point of engraftment. This is of particularly 
importance as engraftment of HSPC is transient, with ST-HSC providing multi-
lineage engraftment from 6-12 weeks wherein LT-HSC begin to take over and 
enable engraftment beyond into 6 months. Most investigators implement a 12-week 
engraftment window for their analysis.   
 
Despite its drawbacks the immune deficient mouse model is still the best assay 
available for evaluating human haematopoietic cell functionality.  
 
1.1.6 In vitro assays  
In vitro assays are another widely used method for analysing haematopoietic stem 
and progenitor cells. They provide a system for the easy manipulation of culture 
conditions allowing assessment of numerous parameters such as interactions with 
the microenvironment and responses to drug treatments (Barnett et al., 1991). 
Crucially, the long-term culture of primitive haematopoietic cells requires an 
adherent stromal cell layer for sufficient support and maintenance over time. This 
feeder layer aids in mimicking the bone marrow microenvironment and pioneering 
studies originally utilized mesenchymal cells purified from bone marrow (Sutherland 
et al., 1989). Currently, most cultures are done with the immortalized murine 
stromal cell line MS-5 which are able to support human HSC and allow 
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1.2 Acute Myeloid Leukaemia 
1.2.1 Leukaemia: The Disease 
Acute myeloid leukaemia (AML) is a severe malignancy of the myeloid 
compartment resulting in excesses of immature heterogeneous myeloid cells that 
are unable to differentiate. The uncontrolled growth of leukaemic cells infiltrates the 
bone marrow and spills out into the peripheral blood. Current data shows that 
patients under the age of 60 have a 35-40% cure rate, however for patients >60 
years of age this is only 5-15%, showing the outlook for older AML patients still 
remains extremely poor (Dohner et al., 2010).   
 
Prognosis Cytogenetic Abnormality 
Good t(15;17)(q22;q21) PML/RARA 
 t(8;21)(q22;q22) AML1-ETO 
 inv(16)(p13q22)/t(16;16)(p13;q22) 
Intermediate Normal Karyotype 
 Or karyotypes not otherwise categorised as 
good or poor prognosis. 
Poor inv(3)(q21q26)/t(3;3)(q21;q26) 
 add(5q), del(5q), -5 
 -7, add(7q)/del(7q) 
 t(6;11)(q27;q23) KMT2A/MLLT4 
 t(10;11)(p11~13;q23) 
 t(9;22)(q34;q11) 





Table 1.1 MRC prognostic classification of AML based on karyotypes.  
Adapted from (Grimwade et al., 2010). 
 
AML is categorised into prognostic categories based on cytogenetic abnormalities, 
which help predict the outcome and best treatment strategy upon initial screening 
(Byrd et al., 2002). Chromosomal abnormalities have long been recognised as key 
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drivers that cause and promote the leukaemic disease. Good prognosis karyotypes 
consist of the onco-fusion proteins AML1/ETO and PML/RARA and inversions on 
chromosome 16. Cytogenetically normal patients, who make up approximately 40-
50% of cases, are categorised as intermediate risk due to the difficulty to predict 
clinical outcome based on obvious karyotypes and the heterogeneity displayed in 
response to therapy. Lastly, poor risk groups include complex karyotypes with >4 
aberrations and certain specific karyotypes as outlined in Table 1.1.  
 
Due to the advent of deep sequencing techniques the heterogeneous response of 
normal karyotype AML samples was unravelled when it was found that there were 
several gene specific mutations potentially being harboured in each patient 
(CancerGenomeAtlasResearch, 2013), even though compared to other 
malignancies, the mutational burden is quite low (Table 1.2). Many of these 
mutations are now themselves being used as predictive markers and have helped 
shed light on the molecular control of AML, even becoming direct targets for novel 
chemotherapies.  
 
NPM1 is the most commonly mutated gene, present in approximately 30% of 
patients. Mutations result in the abnormal expression of the NPM1 protein within 
the cytoplasm, which helps fuel proliferation (Cheng et al., 2010). Expression 
predicts a favourable outcome and is associated with chemo-sensitivity. However, 
this effect is revoked in the presence of a Fms-Like Tyrosine Kinase 3 (FLT3) 
mutation (Döhner et al., 2005). 
 
Mutations in FLT3 come in two forms: internal tandem duplications (ITD) in the 
juxta-membrane domain or mutations in the second tyrosine kinase domain (TKD). 
Both cause constitutive activation of FLT3 signalling, which promotes blast 
proliferation (Kelly et al., 2002). FLT3-ITD is associated with an increased 
incidence of relapse and the degree to which it acts as a marker for poor prognosis 
relies on the allelic burden and whether the ITD is present in the juxta-membrane 
domain (Gale et al., 2008, Pratcorona et al., 2013).  
 
  
Chapter 1 Introduction 
27 
 
Gene Overall Frequency 




















Table 1.2 Frequency of gene mutations in AML.  
Adapted from Molecular therapy for acute myeloid leukaemia (Coombs et al., 2016).  
 
Mutations in DNMT3A, IDH1/IDH2 and TET2 are all involved in epigenetic changes. 
DNMT3A, which codes for a DNA methyltransferase, conveys an adverse 
prognosis after acquisition of missense mutations (Marcucci et al., 2012). Mutations 
in the isocitrate dehydrogenase 1 and 2 genes cause gain-of-functions of the 
enzymes they code for which acquire the new ability to catalyse the reduction of α-
KG to 2-hydroxyglutarate (2HG) (Cairns and Mak, 2013). 2HG is an oncometabolite 
with the ability to inhibit TET enzymes resulting in hypermethylation phenotypes. As 
well as the effect of IDH1 on TET enzymes, loss of function mutations in TET2 are 
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evident, however the prognostic significance of this is still unclear (Chou et al., 
2011, Metzeler et al., 2011).  
 
1.2.2 Leukaemic Initiating Cells: The Hierarchy 
Just like their normal counterparts, AML cells are arranged in a hierarchical nature 
with stem-like leukaemia initiating cells (LIC) at the apex, giving rise to more 
differentiated tumour cells. Thus creating a malignant mimicry of the normal 
haematopoietic system.  
 
The original model established stated that all LICs were contained within the 
CD34+CD38- compartment (Bonnet and Dick, 1997), similar to normal HSC 
hierarchy. However this paradigm was challenged when it was observed that using 
the anti-CD38 antibody during population sorting was inhibiting the engraftment of 
CD38+ samples into mice, in both AML and normal cord blood samples (Taussig et 
al., 2008). This led to the discovery that LICs could also be CD34+CD38+, 
revealing a more heterogeneous nature to LICs then realized before. Yet 
repopulating cells weren’t just restricted to the CD34+ compartment as improved 
xenograft models showed CD34- AML cells could also have LIC activity (Martelli et 
al., 2010, Sarry et al., 2011). As well, it is now known that specifically LIC can arise 
from normal LMPP and GMP populations, and coexist in the same sample 
(Goardon et al., 2011b).  
 
It is generally believed that the LIC is the main contributor to relapse of AML post 
treatment due to the expression of a stem-like gene signature causing the LIC to 
have a more quiescent state than its blast progeny (Eppert et al., 2011, Kreso and 
Dick, 2014). Indeed gene signatures of LSC from the study by Eppert et al. were 
found to most closely resemble that of normal healthy HSC. However Goardan et al. 
showed that CD34+ LSC more closely correlated with progenitor gene signatures, 
with the acquisition of expression of self-renewal genes (Goardon et al., 2011a).  
 
While indeed these studies helped to shed light onto the heterogeneous origin of 
the LIC and how it might be regulated, over the last few years evidence of a ‘pre-
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leukaemic stem cell’, with mutations in NPM1 and TET2 was described (Jan et al., 
2012). Work by Shlush et al. also defined a population of pre-leukaemic stem cells, 
which held DNMT3A mutation, but had not yet progressed to a full leukaemic 
disease (Shlush et al., 2014). Highly purified HSC, progenitors and mature 
hematopoietic cells from the blood of an AML patient showed the presence of 
DNMT3A mutation at high allele frequency, but no NPM1 mutation, which was 
present within the AML blasts of the same patient. The DNMT3A mutant HSC had 
multi-lineage potential when engrafted into mice and showed a repopulation 
advantage over healthy HSC counterparts and when the patient was in remission, 
clones were still present in the bone marrow. These pre-leukaemic HSC have 
helped to show a role for commonly observed mutations in initiation of AML.  
 
1.2.3 Therapeutic Regimes 
The backbone of treatment for AML has remained relatively unchanged for 
decades. Standard induction therapy for AML utilises the “7+3” regime of 3 days of 
anthracycline treatment from either daunorubicin or idarubicin and seven days of 
continuous Ara-C treatment (Cheson et al., 2003). This system is able to achieve a 
complete remission in around 65%–73% of young patients and only 38%–62% of 
patients over 60 years of age. As these regimes can be quite harsh, elderly 
patients require having their fitness tested first and if deemed unfit will be put on a 
lower dose regime.  
 
To prevent relapse and eliminate minimal residual disease after a remission has 
been achieved, patients under go consolidation therapy, which uses intermediate 
dose Ara-C twice daily on a cycle every 2 days (Byrd et al., 2002). This has shown 
to be an effective regimen for good risk patients under 60 years of age. However, 
for intermediate and high-risk patients allogeneic bone marrow transplant remains 
the most effective long-term cure (Popat et al., 2012). Indeed, upon relapse many 
patients become refractory to treatment and a bone marrow transplant is the only 
hope for these patients.  
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1.3 DNA Damage Response and DNA Repair Mechanisms  
DNA is essential for the on-going development, maintenance and reproduction of 
all life forms. Each day the cells in the human body receive masses of DNA lesions, 
which if left unchecked can endanger the viability of the cell or whole organism 
through mutations or larger genomic aberrations. These insults to DNA can come 
from multiple sources such as replicative stress, exposure to UV light, ionizing 
radiation or reactive oxygen species to name but a few. Lesions most commonly 
come in the form of single-strand DNA breaks (SSBs) and in more severe cases 
double strand DNA breaks (DSBs), which are more lethal and difficult for the cell to 
repair. Fortunately cells have formed highly effective DNA damage response and 
repair mechanisms to aid in combatting the diverse range of ways DNA lesions can 
arise and to protect from the daily onslaught of stresses. However, any alterations 
in these pathways can lead to the creation of mutations, which may aid in the 
formation and progression of diseases such as cancer. Therefore it is in the cells 
best interest to effectively manage and repair any DNA damage occurred and 
maintain genomic integrity for the health of the organism.  
 
1.3.1 DNA Damage Response  
The DNA damage response is a highly evolved and concerted mechanism for the 
detection of DNA damage. From the recognition of DNA damage to the promotion 
of repair, it orchestrates a wide range of signals to ensure the appropriate response 
is achieved. Key molecules in the process are the serine/threonine kinases ATM 
and ATR, which are activated by the presence of DSBs and SSBs respectively 
(Cimprich and Cortez, 2008, Shiloh, 2003). DSBs are recognised by the MRN 
complex (formed of MRE11-RAD50-NBS1), which helps act as a bridge between 
the DSB and recruits ATM. This allows ATM to phosphorylate many downstream 
targets, such as the histone H2A variant on serine 139, which acts as a good 
experimental marker for DSBs (Savic et al., 2009). Whereas SSBs recruit ATR 
through the recognition of RPA proteins binding to ssDNA (Zou and Elledge, 2003). 
In response to DNA damage two of the main molecules that ATR and ATM activate 
are CHK1 and CHK2 respectively (Shiloh, 2003), however evidence has suggested 
that this is not a mutually exclusive activation an there is overlap between the 
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pathways (Abraham, 2001). These protein kinases help reduce levels of cyclin-
dependent kinases (CDKs) so cells with DNA damage will halt cycling at key cell 
cycle checkpoints and allow themselves time to repair (Bartek and Lukas, 2007). 
One way they do this is by phosphorylating the phosphatase Cdc25A, which 
targets it for proteolytic degradation, thus stopping it promoting the G1/S phase 
transition by dephosphorylating Cdk2 or the G2/M transition by dehosphorylating 




Figure 1.3 Components of the DNA Damage response. 
DNA breaks are recognised by the serine/threonine protein kinases ATM and ATR. 
They phosphorylate Chk1 and Chk2 proteins which act as transducers to activate 
effectors such as p53 and Cdc25A to exert their effects on cell cycle checkpoints and 
co-ordinate how the cell overcomes the DNA damage.  
 
The CHK1/2 proteins have also been shown to mediate part of their effect through 
phosphorylation of p53, a well-studied and integral player in the DNA damage 
response often called the ‘Guardian of the Genome’ (Shieh et al., 2000, Lane, 
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1992). Upon activation, p53 can orchestrate an extremely vast and complex set of 
responses to DNA damage through its action as a transcription factor and aids the 
cell in the decision to either repair any DNA damage incurred or to initiate 
apoptosis making it a potent tumour suppressor. Two of the most well recognised 
genes that have been implicated in this process, and are transcriptionally regulated 
by p53, are p21 and PUMA. PUMA (p53–up-regulated modulator of apoptosis) is a 
BH3 family protein, which induces apoptosis through the mitochondrial pathway 
(Yu and Zhang, 2003), while expression of p21 induces a growth arrest at the G1/S 
phase, allowing time for the decision to enter into DNA repair or senescence 
(Barboza et al., 2006). However, in what way p53 fully mediates these effects and 
the downstream pathways it influences in the decision between DNA repair and 
apoptosis are still under intensive investigation.  
 
1.3.2 DNA Repair Mechanisms 
There are several mechanisms of DNA repair to deal with the different types of 
lesions DNA can acquire. Base excision repair (BER) excises single nucleotide 
bases that have become chemically damaged, such as 8-oxoguanine, and relies on 
DNA glycosylases to ‘flip’ the damaged base out from the DNA (Hitomi et al., 2007). 
Mismatch repair (MMR) corrects the misincorporation of bases during DNA 
replication and any insertion/deletion loops formed by slippage of the polymerase 
during repetitive sequences. This process is highly conserved from E.coli to 
humans and is regulated primarily by the MutS and MutL components (Li, 2008). 
Nucleotide excision repair (NER) differs from BER in that it primarily repairs bulky 
adducts that distort the DNA helix. These can be caused by 6-4 photoproducts from 
UV damage, pyrimidine dimers and DNA crosslinks (Costa et al., 2003).  
 
Double strand breaks are prepared by either homologous recombination (HR) non-
homologous end joining (NHEJ). HR repair is the restricted to the S-G2 phases of 
the cycle and uses the undamaged sister chromatid as a template for accurate 
repair (Li and Heyer, 2008). Upon the detection of DNA damage the MRN complex  





Figure 1.4 DNA double strand break repair mechanisms: Non-homologous end 
joining and homologous recombination.  
Adapted from ‘Double-strand break repair: 53BP1 comes into focus.’ (Panier and 
Boulton, 2014).  
 
recruits the exonuclease Exo1, which resects the ends of the DNA breaks to single 
strands that become coated with RPA protein. Mediated by BRCA2 and Rad52, the 
RAD51 recombinase is recruited to the DNA break to begin strand invasion of the 
sister chromatid and the damaged DNA is re-copied from the undamaged template 
(Sugiyama and Kowalczykowski, 2002). On the other hand NHEJ is a more error-
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prone form of repair, which directly ligates the DNA break back together with 
minimal end processing (Lieber, 2010b). This process can take place during any 
phase of the cell cycle. The Ku70/Ku80 heterodimer binds directly to the exposed 
DNA ends and recruits the catalytic subunit DNA-PKcs that holds the DNA together 
and recruits end-processing factors, which may result in the loss of some DNA 
bases. The final step requires recruitment of the XRCC4/DNA Ligase IV complex, 
which ligates the DNA back together (Ahnesorg et al., 2006).  
 
1.3.3 DNA Damage Response and Repair in the Haematopoietic System 
The blood is a highly regenerative tissue compartment and the HSC must function 
throughout its life to sustain an on-going haematopoiesis. Preceding the discovery 
of the HSC it was observed that survivors of the Hiroshima bombings, who were 
exposed to persistent low doses of irradiation, most often died of haematopoietic 
failures. This led to work in bone marrow transplants and development of assays 
for studying the radio-sensitivity of haematopoietic cells (Jacobson et al., 1950). 
While it has been known for decades that primitive haematopoietic cells in the BM 
are exquisitely sensitive to DNA damage insult by irradiation, the mechanisms 
surrounding this are only beginning to be unravelled. For their on-going function it 
is paramount HSC ensure they maintain genomic integrity as any mutations or 
DNA damage incurred can be passed down to more differentiated daughter cells. 
 
A number of protective properties have been shown to aid in avoiding the 
accumulation of DNA damage in HSCs. Such as HSC are known to reside in 
hypoxic niches and maintain low levels of metabolic rates, which limits exposure to 
reactive oxygen species (ROS) (Kocabas et al., 2012, Suda et al., 2011) and are 
primarily quiescent, which reduces replicative stress (Wilson et al., 2008).  
 
In response to irradiation it has been shown that human CB cells presented 
differential responses when comparing HSC and progenitor populations (Lin-
CD34+CD38+) (Milyavsky et al., 2010). HSC underwent apoptosis more readily 
than progenitors and displayed persistence of γH2AX foci. This was shown to be 
exerted via a p53-dependent mechanism, as knockdown of p53 or up-regulation of 
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Bcl-2 abrogated this effect. Analysis of global expression profiles highlighted the 
expression of a molecular regulator of p53, known as ASPP1 (apoptosis-
stimulating protein of p53), that was more highly expressed in the HSC than 
progenitor populations and was responsible for the priming of human HSC to 
apoptosis (Milyavsky et al., 2010).  
 
At the same time a study on the murine HSC response to irradiation was also 
published which showed the opposite result, however they compared HSPC with 
myeloid progenitors CMP and GMPs (Mohrin et al., 2010). The myeloid progenitors 
were shown to have a higher induction of apoptosis compared to HSPCs and 
increased expression of pro-apoptotic genes, thus making them more primed for 
cell death in response to DNA damage. Analysis of p53 showed it was active in all 
the populations in response to irradiation, yet was causing a p21 mediated growth 
arrest in HSPC and inducing apoptosis in the myeloid progenitors, showing a dual 
role for p53 in murine haematopoietic cells.  
 
Another study went deeper into the murine phenotype and saw that murine LT-
HSCs, in response to irradiation, was also apoptosis resistant. However in contrast 
to the previously described study, they did not activate p53 (Insinga et al., 2013). 
There was also a large increase in p21 expression, which was upregulated in a 
p53-independent manner, and induced symmetric division. As the previous study 
by Mohrin et al., only analysed HSPC populations, this p53-independent 
mechanism was no doubt masked by the heterogeneity of the populations being 
analysed. However recent work by Yamashita et al., added another layer of 
complexity onto this story by showing the murine LT-HSC predominantly expressed 
Aspp1 compared to progenitors and underwent apoptosis mediated by p53 
(Yamashita et al., 2015). While this falls in line with what was observed in the 
human CB model, there still appears to be many discrepancies as to how primitive 
haematopoietic cells respond to insult from DNA damage by irradiation.  
 
Although there are conflicts as to whether HSCs should survive in response to DNA 
damage, it is also shown that DNA repair mechanisms are playing an important 
role in HSC genomic maintenance. In the same study by Mohrin et al., analysis of 
DNA repair mechanisms showed that quiescent HSPC populations had enhanced 
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NHEJ repair compared to progenitors and when pushed to cycle, HR repair was 
preferentially used (Mohrin et al., 2010). As NHEJ is an error-prone form of repair 
this allowed for the acquisition of mutations and chromosomal aberrations in 
quiescent cells. However cells that were pushed to cycle acquired fewer mutations 
due to the use of the higher-fidelity HR repair.  
 
One of the markers of an aged HSC is the accumulation of DNA damage 
evidenced by persistent γH2AX foci (Rossi et al., 2007, Rube et al., 2011). 
Beerman et al., showed that during quiescence expression of DNA repair and 
response genes were attenuated, however upon entry into cell cycle aged HSC 
repaired their accrual DNA damage and up-regulated a DNA repair gene signature 
(Beerman et al., 2014). It appears that aged HSC are able to persist in a quiescent 
state with accrual DNA damage, apparently going against what is believed about 
HSCs aiming to protect their genomic integrity for the sake of the haematopoietic 
system. As well, recent work by Moehrle et al. has show that the integrity of DNA 
repair between young and aged mice is the same, with HSC being resilient to 
acquiring mutations, something that does not change in the aged HSC (Moehrle et 
al., 2015). Therefore the paradigm of aging, which posits that DNA damage 
persistence in quiescent cells is leading to age-associated mutations that are seen 
in myelodysplastic syndrome (MDS) and AML (Jan et al., 2012, Will et al., 2012), 
requires further investigation.  
 
Mutations or deletions in DNA repair and response genes have been shown to 
have negative effects on HSC function. Fanconi Anaemia (FA) is a rare inherited 
condition where there can be mutations in any one of up to 12 FA proteins, 
including BRCA2, all of which are involved in DNA repair from damage caused by 
cross-linking agents or ROS (D'Andrea and Grompe, 2003). Patients present with 
progressive bone marrow failure and pancytopenia and display a high risk of 
developing neoplasms such as MDS and AML (Mathew, 2006). MDS itself is a 
genomic disability disorder with a high propensity for developing into AML with the 
sequential acquisition of co-operating mutations (Zhou et al., 2013). Recurrent 
mutations in genes involved in histone modifications such as EZH2 or DNA 
methylation such as TET2, show as well a potential link for epigenetic regulation of 
progression of the disease into AML (Graubert and Walter, 2011).  




1.3.4 DNA Damage and Repair in Acute Myeloid Leukaemia 
It’s clear to see that DNA damage plays an integral role in the disease progression 
of AML. As outlined in the previous sections on AML, the disease is categorised 
based on chromosomal aberrations and mutational status due to their influence on 
prognosis and overall survival. Components of the DDR are very rarely mutated in 
AMLs yet an increasing amount of evidence is showing that aberrant epigenetic 
control, based on chromosomal translocations often involving epigenetic regulators 
and transcription factors (TF), create global gene expression changes which can 
influence DDR genes (Cheung and So, 2011, Krivtsov and Armstrong, 2007). 
 
The AML1/ETO fusion onco-protein exerts it epigenetic effects by recruiting HDAC 
complexes to its AML-1 TF binding sites (Davis et al., 2003). It has been shown 
that presence of AML1/ETO alone is not enough to induce a malignancy, and other 
genetic alterations are required for a full disease initiation. Alcalay et al. showed 
that genes involved in BER, such as OGG1, are down regulated by AML1/ETO, as 
well as ATM, an important mediator of the DDR (Alcalay et al., 2003).   
 
PML/RARA is another fusion onco-protein that exerts effects on the transcription of 
DNA repair genes via histone modifications (Casorelli et al., 2006). There is down 
regulation of a number of components involved in HR and NHEJ repair such as 
BRCA1 and DNA-PK. The fusion partner PML is also known to have a functional 
role in HR as a stabiliser of RAD51 (Boichuk et al., 2011), and leukaemia’s with 
PML/RARA were revealed to have a reduction in the activity of HR repair, 
potentially leading to genome instability and accounting for the accumulation of 
DNA damage see in these cells (Viale et al., 2009). There is also strong p21 
expression, independent of p53, in both PML/RARA and AML/ETO leukaemia’s, 
which provides protection from further accumulation of the high amounts of DNA 
damage they already display. This oncogenic cell cycle restriction is believed to 
help maintain leukaemic populations and protect from DNA damage induced 
apoptosis (Viale et al., 2009).  
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Within MLL rearranged leukaemia’s, there are dozens of different fusion partners, 
with many involved in recruitment of chromatin re-modellers such as the histone 
methyltransferase DOT1L (Deshpande et al., 2013). MLL fusion proteins have 
been shown to suppress p53 transcriptional activity by preventing its acetylation 
upon DNA damage, meaning p21 cannot be induced and DNA will accrue un-
repaired (Wiederschain et al., 2005).   
 
 
However it’s not just AML patients with genomic rearrangements that are 
manipulating DDR to their advantage. Presence of the FLT3-ITD mutation has 
been shown to confer resistance to cytotoxic agents, potentially due to up 
regulation of RAD51 (Bagrintseva et al., 2005). As well, mutant IDH1, a common 
driver of AML, usually exerts its effects through inhibition of TET2. Yet it was 
recently shown that IDH1 can provide it’s own influences by down regulating the 
expression of ATM thus impairing DNA repair activation and increasing sensitivity 
to DNA damage (Inoue et al., 2016). 
 
Complex karyotype AML samples are particularly refractory to chemotherapeutic 
treatment. One of the most common genomic abnormalities in this subgroup is the 
loss of 5q, which accounts for the reduced expression of two important DDR genes 
RAD50, part of the MRN complex, and XRCC4 (Lindvall et al., 2004). When DNA 
damage was analysed in a large panel of complex karyotype AML samples these 
patients were found to have high levels of constitutive DNA damage and activated 
Chk1 (Cavelier et al., 2009). This aberrant checkpoint activation provided increased 
resistance to Ara-C treatment that could be abrogated upon inhibition of Chk1.  
 
DNA damage response and repair mechanisms in AML are clearly intertwined with 
epigenetic events. Compromised DDR is evidently helping to promote leukaemic 
transformation, aid disease progression and resistance to chemotherapy.    




Chapter 2. Materials & Methods 
2.1 General Lab Equipment 
Suppliers of materials and reagents are provided below in the relevant methods 
sections. All plastic ware and tissue culture vessels were purchased from Becton 
Dickinson (Plymouth, UK) and Corning Life Sciences. Centrifugation of cell 
suspensions were performed in either an Allegra 6R or Allegra X-12 Beckman 
Coulter centrifuges.   
 
2.2 Cell Culture 
2.2.1 Cell line Maintenance 
All cells were cultured at 37oC and 5% CO2 in humidified incubators. All human 
leukaemic cell lines were maintained in RPMI (Gibco) supplemented with 10% 
foetal bovine serum (FBS) (Gibco) and 1% penicillin/streptomycin (Gibco). Cells 
were passaged every 2-3 days to maintain them at optimal density. Murine MS5 
cells were maintained in IMDM (Gibco) with 10% FBS and 1% 
penicillin/streptomycin. Adherent cells were passaged by trypsinisation and 
maintained at sub-confluency.  
2.2.2 Freezing and Thawing Stocks 
Cells for cryopreservation were harvested at low passage number, pelleted at 
300xg and resuspended in 500 µl FBS in a cryotube. An equal volume of FBS with 
20% dimethylsulfoxide (DMSO) was added and mixed by pipetting. Cryotubes were 
placed into a cryobox containing isopropanol and placed at -80oC for a minimum 3 
days. For long-term storage cells were then subsequently transferred to liquid 
nitrogen.  
Frozen vials were thawed in 37oC water bath and cell suspension was added drop-
wise to warm complete medium in a 15ml falcon to dilute the DMSO. Cells were 
then centrifuged and resuspended in an appropriate volume. 
 




2.3 Umbilical Cord Blood Cells 
2.3.1 Source of Samples 
Umbilical cord blood was collected from mothers giving birth at the Royal London 
Hospital, in accordance with a protocol approved by the East London and 
Research Ethics Committee. Informed and written consent was obtained prior to 
collection of samples.   
2.3.2 Separation of mononuclear cells by Ficoll density centrifugation 
Cord blood samples were pooled and diluted 1:2 with PBS. 15 ml of Ficoll (GE 
Healthcare) was dispensed into 50 ml Falcon tubes and 35 ml of diluted cord blood 
was slowly layered over the Ficoll. The tubes were then centrifuged at 1600 RPM 
for 30 minutes at room temperature with slow deceleration. 
The layer of mononuclear (MNC) cells was carefully removed with a plastic Pasteur 
pipette and transferred to a new 50 ml Falcon tube containing 25 ml of 2% 
FBS/PBS solution to dilute the remaining Ficoll and centrifuged (300xg for 5 
minutes). Remaining erythrocytes were lysed with ammonium chloride for 10 
minutes at room temperature and the reaction stopped with the addition of FBS. 
The mononuclear cells were pelleted and resuspended in PBS with 2% FBS for 
counting using a haemocytometer.  
 
Cells were then either frozen or purified based on immunogenic markers.  
2.3.3 CD34 Positive Purification 
Fresh MNC that had been separated from cord blood were selected for CD34+ 
cells using EasySep Human CD34 Positive Selection kit (Stem Cell Technologies, 
Vancouver) according to manufacturers instructions. All steps were performed 
using 2% FBS/PBS. Cells were first incubated with EasySep Positive Selection 
Cocktail at room temperature for 15 minutes and then with EasySep Magnetic 
nanoparticles at RT for 10 minutes. The stained cells were then placed into an 
EasySep Magnet for 5 minutes before unselected cells were discarded and CD34+ 
remained magnetically held to the inside of the tube. The tube was then removed 
from the magnet and cells resuspended. This was repeated at least 5 times to 




ensure a high purity of CD34+ cells. Purity checks were done by FACS before 
freezing down the cells down in aliquots. 
 
2.4 Acute Myeloid Leukaemia Samples 
AML cells were obtained after informed consent from patients attending St 
Bartholomew’s Hospital, London, under a protocol approved by the East London 
and City Research Ethics Committee. Frozen samples were thawed as described 
in the previous section.  
 
2.5 In vitro assays 
2.5.1 Culture of primary haematopoietic cells 
If culturing cells longer than one-week culture dishes were coated with collagen 
solution (0.3 mg/ml), left to dry then rinsed with PBS. MS-5 cells could then be 
plated in IMDM (supplemented with 10% FBS, 1% PenStrep) and left to reach sub-
confluency before irradiation with 6.8 Gy from a 137Caesium source (IBL 637 
Gamma Irradiator) to inhibit further growth.  
Freshly thawed positively selected CD34+ UCB cells were resuspended and 
cultured in Myelocult™H5100 media (Stemcell Technologies) containing 1% 
PenStrep. Cells were counted on a haemocytometer with trypan blue exclusion and 
before plating on the MS-5 stromal layers at a density of 1-2x103 cell/cm2. Cultures 
were left for a minimum of 3 days before any assays were performed. Ara-C 
(Sigma Aldrich) was diluted in H2O and added directly to cultures at a final 
concentration of 500 nM.  
 
2.5.2 Culture of primary acute myeloid leukaemia samples 
Stromal layers were prepared as described above. AML samples were thawed (as 
previously described) and suspended in Myelocult™ H5100 medium (1% 
PenStrep) for counting with trypan blue exclusion using a haemocytometer. Cells 
were resuspended to appropriate volume in Myelocult™ supplemented with a 




cocktail of cytokines: 20 ng/ml IL-3, 20ng/ml GCSF and 20 ng/ml TPO (PeproTech, 
London, UK). Samples were plated onto stromal layers at a density of 2.5-5x105 
cell/ml. For drug treatments, Ara-C (Sigma Aldrich) was diluted in H2O and added 
directly to cultures at a final concentration of 500 nM. 
 
2.6 In vivo assays 
2.6.1 Mice 
All work was performed in accordance with Home Office regulations with the 
approval of the Francis Cricks Institutes ethics committee. NOD.Cg-Prkdcscid 
Il2rgtm1Wjl/SzJ (NOD/SCID/IL2 receptor 2 gamma chain null, NSG) mice were bred 
at the Clare Hall Laboratories, Francis Crick Institute. Mice were transferred to the 
animal facility at 7-8 weeks old and housed in sterile conditions and fed acidified 
water.  
2.6.2 Primary Transplantation 
24 hours prior to transplantation 8-12 week old mice were sublethally irradiated 
with 3.75 Gy from a 137Caesium source (IBL 637 Gamma Irradiator). The mice were 
administered prophylactic antibiotics (Baytril 2.5% via drinking water) three times 
per week for two weeks after irradiation. 
Samples were prepared in 2% FBS/PBS with DNase to inhibit cell clumping. For 
purified CD34+ cells, 50,000 cells per mouse in a volume of 150 ul were injected. 
Human AML patient samples were depleted for CD3+ cells prior to injection by 
using the Okt3 antibody (BioXCell) at a concentration of 1 ug per 1x10^6 of cells. 
The sample was incubated at room temperature for 30 minutes and taken directly 
for injection.  
 
Mice were first warmed in a heat box to 38oC to dilate the tail vein and cells were 
injected intravenously with a 30 G needle and 0.5 ml syringe.  




2.6.3 Analysis of human engraftment 
Engraftment of human cells in the murine bone marrow was assessed 12 weeks 
post injection. Mice were sacrificed by cervical dislocation and tibia, femur and ilium 
dissected bilaterally. Bone marrow was harvesting by flushing the bone cavity with 
2% FBS/PBS using a 30 G needle and 1 ml syringe, each mouse was processed 
individually. Remaining erythrocytes were lysed with 2-3 ml of ammonium chloride 
for 3 minutes at room temperature. The reaction was stopped by addition of 500 ul 
FBS and cell were pelleted. The sample was then processed for FACs analysis as 
described in the next section. Antibodies used are listed in Appendix 7.2.  
 
2.7 Flow Cytometry 
2.7.1 Extracellular Staining and Analysis Parameters 
Cells were incubated with antibodies at room temperature for 15 minutes, or 4oC for 
30 minutes, in the dark in 50 µl 2% FBS/PBS. Samples were subsequently washed 
and suspended in DAPI (4’, 6’-diamidino-2-phenylindole) at concentration 100 
ng/ml in 2% FBS/PBS and analysed on a LSRII flow cytometer (BD Biosciences). 
For multicolour experiments single colour controls of stained OneComp 
compensation beads (eBiosciences) were used for compensation of flourochromes. 
Gates were set to exclude non-viable cells, debris and doublets during analysis. 
CountBright™ Absolute Count beads (Life Technologies) were used to quantify 
different populations. A minimum of 104 events from the gate of interest was 
recorded for each sample.  
2.7.2 AnnexinV Staining 
Cells were first stained for extracellular antigens as previously described, if 
required. Cells were washed in PBS and resuspended in 30-50 µl AnnexinV 
staining buffer 10x (BD Pharmingen) diluted 1:10 in distilled water. 5 µl of anti-
AnnexinV-APC was added and cells incubated in the dark at room temperature for 
15 minutes. Cells were not washed and 300 µl of 1 x Annexin Staining buffer with 
DAPI 100 ng/ml was added to the sample and analysed straight away. An 
unlabelled sample was used as a negative control. Live cells undergoing apoptosis 




were identified as DAPI negative and AnnexinV positive. DAPI and AnnexinV 
double positive cells were classed as dead.  
2.7.3 Intracellular Staining  
Cells were first stained for extracellular markers, washed with PBS and fixed with 
PFA (Para-formaldehyde) at room temperature for 10 minutes. Cells were washed 
in PBS and permeabilised with PBS containing 0.1% Triton-X100 for 10 minutes at 
room temperature. The reaction was stopped by washing with 2% FBS/PBS. 
Samples were split into two and stained with appropriate isotype control and target 
antibody for 1 hour at 4oC. Cells were washed with 2% FBS/PBS and resuspended 
in DAPI 1 µg/ml with 2% FBS/PBS and analysed.  
2.7.3.1  γH2AX Staining 
For analysis of phosphorylation of H2AX cells were fixed at 37oC for 10 minutes 
using PFA. Cells were washed with PBS and permeabilized with 0.1% Triton X-100 
for 10 minutes at room temperature. Samples were split in two and stained with 
either 1 µl γH2AX-Alexa647 or 0.5 µl isotype control Alexa647 for 1 hour at 4oC in 
2% FBS/PBS. Cells were washed and resuspended in 300 µl 2% FBS/PBS with 
DAPI 1 µg/ml.  
2.7.3.2  Ki67 Staining 
For cell cycle analysis cells were fixed and permeabilised as described and stained 
with 10 µl of anti-Ki67- FITC or isotype control conjugated to FITC. Staining was 
performed for 1 hour at 4oC. Cells were washed in 2% FBS/PBS and resuspended 
in 300 µl 2% FBS/PBS with DAPI 1 µg/ml. 
2.7.4 Cell Sorting 
Cells were stained as previously described and as appropriate for the assay. 
Samples were resuspended in 1 ml DAPI 100 ng/ml in 2% FBS/PBS and filtered 
through a 70 µm mesh filter (BD Biosciences) to remove clumps and samples kept 
on ice. Sorting was performed on either MoFlo XDP (Beckman Coulter), BD FACS 
Aria or BD Influx sorters using a 100 µm nozzle. Collection tubes contained 2% 
FCS/PBS and purity checks were performed to check sort quality.  




2.8 Molecular Biology 
2.8.1 RNA Extraction 
Cells were washed in PBS to remove residual serum spun down. RNA was 
extracted using the Qiagen RNeasy kit according to manufacturers protocol. The 
RNeasy Microkit was used for samples below 5x105 cells and the RNeasy Mini kit 
for samples up to 1x107 cells. RNA was eluted in RNase-free distilled water. The 
RNA concentration and purity was quantified on the Nanodrop 2000c 
Spectrophotometer (Thermo Scientific) by measuring absorbance at 230 nm, 260 
nm and 280 nm. Samples were stored at -80oC. 
2.8.2 Reverse Transcription 
RNA was reverse transcribed to cDNA using Superscript III M-MLV reverse 
transcriptase (Invitrogen), according to manufacturers protocol. A maximum of 5 µg 
of total RNA and oligodT20 primers were used per 20 µl reaction. The reaction was 
incubated for one hour at 50oC, and then inactivated at 70oC for 15 minutes. cDNA 
was stored at -20oC.  
2.8.3 Quantitative real-time PCR  
All quantitative PCR (QPCR) was performed with SybrGreen. Reactions were 
performed in 10 µl reactions with the following components: 5-100 ng cDNA, 
forward and reverse primers at 300 nM each, 5 µl of SYBR® Green Mastermix 
(Applied Biosystems) and distilled water to 10 µl. Reactions were run in duplicate or 
duplicate in 384-well plates. Β-Actin was used as normalization control. Thermal 
cycling was performed in a ViiA™7 Real-Time PCR System (Applied Biosystems).  
 
The run method was as follows: 
Hold Stage - 95.0oC 10:00 minutes 
Cycle x 40 – Denature 95.0oC 15 seconds, Anneal/extend 60.0oC 1 minute. 
Melt Curve – 60oC to 95oC continuous.  
Data was analysed using QuantStudio™ Real-Time PCR software (Applied 
Biosystems).  




2.8.4 RT2 Profiler PCR Array 
The RT2 Profiler PCR array (Qaigen) is a 384-well array that has primers for 
SybrGreen based qPCR pre-loaded into each well. The array contained primers for 
human DNA repair genes and the house keeping genes, ACTB, B2M, GAPDH, 
HPRT1 and RPLP0. Targeted wells were arranged in quadruplicate allowing for the 
analysis of two samples in duplicate on each array plate.    
 
PR reactions were prepared as described before, in 10 µl volume, and pipetted 
directly into the plate before sealing and centrifuging and running on ViiA™7 Real-
Time PCR System (Applied Biosystems) under the conditions described previously. 
Data was analysed with the aid of the Qiagen GeneGlobe Data analysis centre.  
2.8.5 Relative Quantification using 2-ΔΔCt  
Relative gene expression was expressed as fold change relative to the control 
sample with samples normalised to a housekeeping gene. Briefly described, the Ct 
value for the target gene is subtracted from the Ct value of the housekeeping 
control giving the ΔCt. The ΔCt of the test sample is subtracted from that of the 
control sample to give the ΔΔCt. Subsequently the ΔΔCt of the test sample is 
normalised to the control sample and the value is transformed from a logarithmic 
value to linear and expressed as 2-ΔΔCt. 
 
2.9 Immunoflourescence 
Purified cells (2000-50,000) were pipetted onto polysine slides (Thermoscientific) 
and incubated for 20 minutes. Cell were fixed with 2% PFA for 10 minutes at RT, 
then washed with PBS, before permeabilisation with 0.1% Triton X-100 for 10 
minutes at RT. Samples were then blocked for 1 hour at RT in blocking solution 
(see appendix 7.1). Primary antibodies (see appendix 7.2), either used alone or in 
combination were diluted in blocking solution and pipetted onto the slide for 
overnight incubation at 4oC. Slides were washed 3 times with PBS and stained with 
secondary antibodies in blocking solution for 45 minutes at RT, protected from light. 
After a final 3 rounds of PBS washes, slides were mounted with fluorescent 




mounting medium (Dako) containing 500 ng/ml DAPI and placed with coverslips. 
Until analysis slides were kept at 4oC in the dark.  
 
2.10   Microscopy 
2.10.1 Foci Scoring 
Fixed and mounted cells were analysed for foci on an Axioplan2 microscope 
(Zeiss) using 100x magnification. 100 cells were scored by eye per condition in 
each experiment.  
2.10.2 Confocal Microscopy 
Images were captured using the Zeiss LSM710 upright confocal microscope with 
ZEN software (Zeiss) and processed using Imaris (Bitplane) and Adobe Photoshop 
CS5.1 and ImageJ.  
 
2.11   Comet Assay 
Alkaline comet assay was performed using Trevigen CometSlides. Each slide was 
prepared by coating with 1.5% normal melting point agarose and dried overnight. 
Purified cells were resuspended to 1x106 cells per ml in PBS on ice. Positive 
controls were then irradiated at 10 Gy. 20 µl of cell suspension was transferred to 
240 µl of 0.5% low melting point agarose preheated to 37oC. 120 µl of the 
agarose/cell solution was dropped onto each circle of the slide then covered with a 
circular coverslip. The agarose was allowed to set at room temperature for 10 
minutes then coverslips were removed. Slides were placed in cold lysing solution at 
4oC overnight in the dark. A horizontal electrophoresis tank was set up at 4oC in the 
dark and filled with cold electrophoresis buffer. Slides were placed into the tank in 
the same orientation and left for 60 minutes, protected from light, for the DNA to 
unwind. They were run at 20 V constant and 300 mA for 30mins. Post 
electrophoresis slides were neutralized with neutralization buffer for 3 rounds of 5 
minutes. They were then dehydrated in absolute ethanol for 10 minutes and edges 
of the slides were coated with clear lacquer to inhibit the peeling of the agarose and 




left overnight to dry. Cells were stained with ethidium bromide (10 µg/ml) and 
visualized using Zeiss Axioscope microscope at 40x magnification using Comet 
Assay IV software (Perceptive Instruments). 50 cells were randomly scored per 
circle on each slide. Comet tail moment was calculated as DNA migration x Tail 
intensity. See Appendix 7.1 for buffer recipes.  
 
2.12   Statistical Analysis 
The results shown were mean, median or standard deviation values as stated. All 
statistical analyses were performed using GraphPad Prism software. The Student’s 
t-test was used unless indicated otherwise. A p-value <0.05 was considered 
significant.




Chapter 3. Results 1: Response of Acute Myeloid 
Leukaemia Cell Lines to Ara-C Treatment 
 
3.1 Introduction 
Since its introduction into clinics in the 1960s, Ara-C has been a mainstay in 
treatment of AML and is still widely used in most treatment regimes to this day 
(Short and Ravandi, 2016). This acts as a testament to its effectiveness as a 
chemotherapeutic drug, which has helped improve the poor clinical outcome of 
AML patients, with most now able to attain a complete remission. However, long-
term outlook for these patients still remains dismal with a 5 year survival rate of 
25% due to relapse (Howlader N, 2014). Upon relapse the majority of patients 
become refractory to previously used treatments and succumb to their disease, 
with a haematopoietic stem cell transplant usually being the last option available.   
 
Many studies in the past have tried to pinpoint a definitive mechanism for how AML 
cells develop resistance to Ara-C, with much focus being taken on cellular uptake 
and metabolism of the drug. Ara-C is a nucleoside analogue which targets 
proliferating cells by incorporating itself into the cells DNA as the cell replicates 
leading to chain termination and an unstable replication fork which eventually 
breaks down and cause double strand breaks (DSBs) (Robak, 2003). Low 
expression of the human equilibrative transporter (hENT1) (Gati et al., 1997, Gati et 
al., 1998, Wiley et al., 1982), which influxs the drugs. Reduction in activity of 
deoxycytidine kinase (dCK) (Bhalla et al., 1984, Stegmann et al., 1993), which 
phosphorylates Ara-C to it’s active form Ara-CTP. Or even increase in cytidine 
deaminase (CDA) expression (Schroder et al., 1996), which inactivates Ara-C to 
Ara-U. So far all have been suggested as contributing factors to chemoresistance 
based on assessment in cell lines and clinical samples. While these studies have 
presented correlations to adverse drug responses, it appears that no conclusive or 
targetable mechanisms have come to light and resistance is most likely due to the 
contribution of many factors. 




Deregulation of DNA damage response and repair mechanisms are observed in 
most malignancies, wherein defects in these pathways are exploited by many 
cancer therapies, which utilise DNA damaging approaches, and have been heavily 
implicated in chemotherapy response and resistance (Bouwman and Jonkers, 
2012). These irregularities are particularly evident in leukaemia’s which inherently 
accumulate chromosomal aberrations. Ara-C primarily works by its cytotoxic effects 
of incorporating into DNA at the S-phase of the cell cycle, blocking replication and 
damaging DNA (Kufe et al., 1980). Thus in its ability to cause DNA damage, a 
possible factor in resistance to Ara-C treatment could potentially be found by 
studying DNA damage response and repair mechanisms.   
 
The use of AML cell lines was therefore deployed as an initial study into the effect 
of Ara-C on normal and malignant haematopoietic cells and DNA damage 
responses.  
  





3.2.1 Survival of AML cell lines post Ara-C treatment 
As an initial screen AML cell lines were utilised due to the abundance of cells 
available and for easy optimisation of techniques without wasting valuable primary 
material. As well, all in vitro assays were performed on MS-5 stromal layers to 
better mimic the bone marrow environment creating a more physiologically relevant 
assay. Previous work has shown that the stroma has a protective effect on 
leukaemic cells in response to chemotherapy (Konopleva, 2002), however for the 
scope of this study the microenvironment interactions will not be assessed as the 
focus will be on more cell intrinsic properties of DNA damage response.  
 
 
Figure 3.1 Viability screen of a cohort of acute myeloid leukaemia cell lines post 
Ara-C treatment. 
Measurement of viability by XTT assay, 24 hours post varying doses of Ara-C 
treatment in vitro. Normalised to untreated control. (n=2).  
 
After a pre-screening of several AML cell lines, a cohort of three was selected 
based on their viability after varying doses of Ara-C treatment (Figure 3.1). The HL-
60 cell line is an acute promyelocytic cell line with a complex karyotype and 
amplified c-myc expression (Favera et al., 1982). ML-1 is a myeloblastic cell line 
harbouring a MLL-AF6 chromosomal translocation (Strout et al., 1996) and the 




U937 cell line, although originating from a histiocytic lymphoma (Sundstrom and 
Nilsson, 1976), displays myelomonocytic characteristics with presence of the 
leukaemic fusion oncogene CALM/AF10 (Dreyling et al., 1996) and is often used in 
studies of AML.  
 
 
Figure 3.2 Schematic of in vitro treatment protocol for acute myeloid leukaemia 
cell lines.  
Cell lines were plated on MS-5 stromal cell layers before treatment with Ara-C. 
Samples were taken at 24 and 96 hours post treatment.  
 
 
Outlined in Figure 3.2 is the treatment protocol created to examine how AML cell 
lines respond to treatment of Ara-C in vitro. Irradiated MS-5 stromal layers were 
prepared for pre-plating of cell lines, which undergo overnight incubation on stroma, 
before addition of Ara-C. 
 
It has been shown clinically that patient plasma levels of Ara-C, after a standard 
dose regime, can reach the range of 0.5-1 µM (Weinstein et al., 1982). Therefore, 
various doses of Ara-C were tested (Figure 3.1) before resolving on the lower 
concentration of 0.5 µM, which provided a dose in which adequate material could 
be collected for analysis post treatment. 
 




As Ara-C works through its incorporation into proliferating cells, it is important to 
compare two time points, of early (24 hours) and late (96 hours), to ensure 
sufficient exposure of the drug.   
 
 
Figure 3.3 Cell count of AML cell lines post Ara-C treatment.  
Cell counts at 24 and 96 hours for AML cell lines co-cultured on MS-5 stromal cells 
in treated (Ara-C 500 nM) or untreated conditions (n=3). *p<0.05, **p<0.005. Error 
bars are ± S.D (standard deviation of the mean). 
 
 
After treatment under the conditions outlined, analysis of cell number by FACS 
(flow cytometry) compared to untreated showed varying reductions up to 96 hours 
across the panel (Figure 3.3). While the majority of the cell lines showed a 
continual reduction over time in cell number in the Ara-C treated cells, U937 cell 
line was much less responsive showing no significant differences compared to 
untreated (24 hours: p=0.119, 96 hours: p=0.22). All the other cell lines showed 
varying reductions in cell number, with HL60 cells appearing to be the most 
sensitive, with the former becoming almost completely diminished by 96 hours. 
Even though ML-1 cells showed a significant reduction in cell number at 24 hours 
(*p=0.03), the untreated sample appears to reach a growth plateau by 96 hours.  





Figure 3.4 AnnexinV+ expression post Ara-C treatment in leukaemic cell lines.  
(A) Representative flow cytometry plot of AnnexinV+ and DAPI stained HL60 and 
U397 cell lines under different timepoints and conditions as stated. (B) 
Quantification of frequency of AnnexinV positive and DAPI negative stained AML 
cell lines. Culture conditions were on stromal cell layers over 96 hours in presence 
of Ara-C 500 nM or untreated. ±S.D (n=3), **p<0.005.  
 
Induction of apoptosis, as shown by AnnexinV+ staining, appeared to reflect these 
results (Figure 3.4A). Initially, at 24 hours, slight increases but no significant 
changes can be seen across the panel of cell lines (Figure 3.4B). Yet by 96 hours, 
HL60 and ML-1 cells displayed an almost 4-fold (**p=0.004) and 2-fold (**p=0.005) 
increase in apoptosis respectively. This is in sharp contrast to U937 which 
displayed no significant differences in either AnnexinV staining (p=0.257) or 
reduction in cell numbers. 
 




These results suggest AML cell lines display different sensitivities to Ara-C based 
on survival post treatment. However, as the action if Ara-C is dependent on the rate 
of proliferation, it is important to determine the cell cycle status of these cells.  
  




3.2.2 Cell cycle profile of AML cell lines post Ara-C treatment 
As shown in section 3.2.1, differences in survival of the AML cell lines in exposure 
to Ara-C treatment could potentially be determined by cell cycle status as action of 
Ara-C is dependent on the cell being in the S-phase. 
 
 
Figure 3.5 Cell cycle profile of Ara-C treated leukaemic cell lines. 
(A) Representative flow cytometry plots of Ki67 and DAPI stained HL60 and U937 
cell lines at indicated conditions. (B) Quantification of Ki67 and DAPI stained AML 
cell lines for analysis of cell cycle profile. Culture conditions were on stromal cell 
layers over 96 hours in presence of Ara-C 500 nM or untreated. ±S.D (n = 3). 
 
Using the same treatment protocol as previously, the different phases of the cell 
cycle were determined by examining Ki67 and DAPI content by FACS (Figure 
3.5A).  
 




Across all cell lines approximately 40% of the cells were within the S-phase at any 
one time, showing equal opportunity for the effect of Ara-C (Figure 3.5B). HL60 
cells appeared to be the only sample, at 24 vs 96 hours Ara-C treated, that showed 
a slight S-phase increase however it was not significant (p=0.8). It has been 
previously shown that Ara-C can cause a block and accumulation of cells in the S-
phase, and frequency of G0 decreases as cells are recruited into active cell cycle 
only to become blocked (van Pelt et al., 2005). At 96 hours in both HL60 and U937 
cells, although not statistically significant, there was a slight reduction in frequency 
of G0 cells in the Ara-C treated compared to untreated (p=0.16) and (p=0.2) cells 
respectively. Unusually ML-1 cells showed minimal if any changes in cell cycle 
status, reflective of the proliferation observed in Figure 3.2.  
 
This data suggests that as the cell lines react in a similar manner regarding cell 
cycle status post Ara-C treatment, with a trend towards reduction in frequency of 
G0 (albeit not significant), other downstream mechanisms may be affecting their 
differential responses to Ara-C.  
 
3.2.3 Ara-C Induces DNA damage in AML cell lines 
As previously outlined, Ara-C is a cytotoxic agent capable of inflicting DNA damage 
through it’s incorporation into replicating DNA causing the destabilisation of 
replication forks and the formation of double strand breaks. Thus, one of the most 
sensitive ways to assess DNA damage is by measuring phosphorylation of the 
histone H2AX on Ser139, which marks a double-strand break (DSB) (Savic et al., 
2009). For easy quantification of DNA damage on low numbers of cells, 
measurement of total levels of γH2AX by intracellular FACS is an extremely useful 
tool (Figure 3.6A). 





 Figure 3.6 Measurement of γH2AX by intracellular FACS post Ara-C treatment in 
AML cell lines.  
(A) Representative phospho-flow cytometry histogram for intracellular staining of 
γH2AX in HL60 and U397 cell lines under different time points and conditions as 
stated. (B) Quantification of γH2AX MFI (mean fluorescent intensity) by geometric 
mean represented as fold difference normalized to untreated. Culture conditions 
were on stromal cell layers over 96 hours in presence of Ara-C 500nM or 
untreated. Error bars represent ± S.D (n=3) *p<0.05.  
 
Using this method AML cell lines were analysed using the same treatment 
schematic outlined in Figure 3.1. At 24 hours post Ara-C treatment all cell lines 
displayed increases in γH2AX signalling (HL60: p=0.1, U937: *p=0.012, ML-1: 
*p=0.02) (Figure 3.6B). By 96 hours this had decreased to insignificance in U937 
and ML-1 cells (p=0.15, p=0.24 respectively), analogous with observations from 
section 3.2.1 where by 96 hours the effect of Ara-C is not as striking as when 
compared to HL60 cells at the same time point.  





Figure 3.7 γH2AX foci counts post Ara-C treatment.  
(A) Representative immunofluorescence staining of γH2AX foci (red) and DNA 
(blue) by DAPI in leukaemic cell lines post Ara-C treatment on stroma. 100x 
magnification. (B) Quantification of number of foci per nucleus 24 hours post Ara-C 
treatment. 100 nuclei were scored for each condition. *p<0.05 (n=3). Error bars 
represent ±S.D.  
 
A more qualitative way of measuring DNA damage is by immunofluorescence and 
visualisation of γH2AX stained foci within the nucleus (Figure 3.7A). Counting the 
foci per nucleus permits a spectrum of how damaged the cell is. In this study a 
score of 0 foci = undamaged, 1-4 = increasingly damaged and >4 = very damaged 
was used to quantify the foci. After 24 hours all samples treated with Ara-C showed 
a significant increase in being ‘very damaged’ (>4 foci/nucleus), compared to 




untreated (Figure 3.7B) (HL60: *p=0.04, U937: *p=0.024, ML-1: *p=0.012). This is 
comparable to when γH2AX is detected by FACS (Figure 3.6) at the same time 
point. 
 
As analysis of γH2AX is only a marker of DNA damage, to be certain of actual 
direct DNA damage, this can be measured by the alkaline comet assay (Figure 
3.8A). As expected significant increases in DNA damage were detected across the 
board, with damage persisting in U937 and ML-1 cells up to 96 hours despite 
reduction in γH2AX by FACS (Figure 3.6B). 
 
 
Figure 3.8 Measurement of direct DNA damage by alkaline comet assay of Ara-C 
treated AML cell lines. 
(A) Representative images of DNA comet tails stained with ethidium bromide under 
different treatment conditions. 10 Gy acts as positive control. (B) Quantification of 
comet tails done by olive tail moment, a measurement of DNA migration x DNA 
density of the comet tail. Leukaemic cells were treated with Ara-C over 96 hours on 
stroma. 100 cells were scored per slide. Error bars represent ±S.D. ***p<0.0005. 
****p<0.0001.  





Overall there is direct evidence that Ara-C induces DNA damage in AML cell lines. 
In U937 and ML-1 cells this appears to be in similar levels as evidenced by γH2AX 
and comet assay. HL60 cells however failed to show an as comparably significant 
evidence of DNA damage; this may be due to the increased apoptosis and 
markedly reduced cell number post Ara-C treatment compared to the other cell 
lines, which means cells are lost during the assay. It appears that even though Ara-
C inflicts DNA damage upon U937 cells, it can tolerate this damage much better as 
it displays no significant reduction in apoptosis or cell number.   




3.2.4 Response of AML cell lines to irradiation induced DNA damage. 
As AML cell lines display different responses to Ara-C it was next investigated 
whether inflicting DNA damage from another source, such as irradiation, would 
elicit similar effects in cell death and resolution of γH2AX. As irradiation induced 
DNA damage is not dependent on proliferation, a shorter time frame of 0 to 48 was 
observed. A dose of 2Gy was chosen as was previously used in haematopoietic 
cell studies (Milyavsky et al., 2010).  
 
Post irradiation a reduction in cell number can be observed in all the cell lines 
(Figure 3.9A) however, much like when treated with Ara-C, HL60 cell line has a 
 
 
Figure 3.9 Effect of DNA damage by irradiation on AML cell lines.  
AML cell lines, grown on stromal cell layers were irradiated with 2 Gy and analysed 
at 0, 0.5, 2, 4, 8, 24 and 48 hours post treatment. (A) Absolute cell count by FACS 
(B) frequency of AnnexinV+ cells (C) Intracellular FACS staining for γH2AX 
normalised to IC (isotype control). 




greater decline in numbers than U937 and ML-1 cells, with the latter cell lines 
showing a stronger kinetic of growth recovery. 
 
The onset of apoptosis, as measured by AnnexinV staining, mirrored the kinetics of 
reduction in cell number (Figure 3.9B). U937 cells, after showing an initial peak at 
24 hours, started to show a decline of apoptosis by 48 hours. HL60 cells showed a 
growing rate of apoptosis up to 48 hours, as did ML-1 cells. Measurement of 
γH2AX by FACS (Figure 3.9C) again showed the U937 cell line was faster at 
responding to irradiation by reducing levels of γH2AX back to untreated by 24 
hours. In contrast, HL60 and ML-1 cells lagged behind taking an extra 24 hours to 
return to near untreated levels of γH2AX.  
 
Overall this shows that DNA damage induced by irradiation produces a similar 
response in AML cell lines to DNA damage that has been inflicted by Ara-C. The 
U937 cell line appears to be impervious and more able to tolerate DNA damage, 
while HL60 cells are more sensitive. ML-1 cells are more difficult to conclude a 
comprehensive answer from, as at times it appears to behave sensitively similar to 
HL60 cells and other times, it responds just like U937 cells.  




3.2.5 AML cell lines initiate DNA Repair in response to Ara-C treatment. 
As mentioned previously γH2AX foci are most primarily symptomatic of DNA DSBs 
(Savic et al., 2009). Analysis by comet assay showed direct DNA damage being 
inflicted by Ara-C treatment as well as increase in γH2AX foci (See Section 3.2.3). 
This ability of Ara-C to create DNA damage by DSBs, yet incur varying survival 




Figure 3.10 DNA Repair Mechanisms post Ara-C Treatment.  
Quantification of number of foci per nucleus, 24 hours post Ara-C treatment. 100 
nuclei were scored for each condition. Error bars represent ± S.D. (n=2-3) *p<0.05. 
(A) Foci counts/nuclei of 53BP1 localisation showing activation of Non-homologous 
end joining repair. (B) Foci counts/nuclei of RAD51 localisation showing activation 
of homologous recombination repair.  
 




The two primary pathways for DSB DNA repair are non-homologous end joining 
(NHEJ) and homologous recombination (HR). To detect their activity, 
immunofluorescence for the nuclear localisation of key proteins 53BP1 for NHEJ 
and RAD51 for HR was performed. These protein form foci at DSBs and are 
indicative of activation of the DSB repair mechanisms. This is a classical way to 
report on the early functions of each pathway and to show which mechanism is 
preferentially used by the cells. 
 
Quantification of foci was done using the same scoring system as for the γH2AX 
immunostaining (0 foci = undamaged, 1-4 = increasingly damaged and >4 = very 
damaged). 
 
Quantification of 53BP1 foci formation post Ara-C treatment only showed significant 
localisation (>4 foci/nuclei) in U937 cells (*p=0.017) in approximately 40% of cells 
(Figure 3.10A). There was evidence of activation of NHEJ repair in HL60 cells, 
however this was insignificant at both high levels (>4 foci/nuclei: p=0.07) and low 
levels (1-4 foci/nuclei: p=0.09) of localisation. ML-1 cells showed no indication of 
repair after exposure to Ara-C. On the other hand, analysis of RAD51 foci formation 
post Ara-C treatment showed no indication of activation of HR repair (Figure 3.10B) 
in any of the cell lines tested. 
 
These results appear to be strong evidence that U937 cells can utilize DNA repair 
mechanisms to potentially overcome the DNA damaging effect of Ara-C. 
  






As a first port of call, leukaemic cell lines were used to discern the response of 
chemotherapeutic treatment with Ara-C, specifically looking at activation of DNA 
damage and repair mechanisms.  
 
It was initially observed that by culturing in vitro in presence of Ara-C, cell lines 
displayed differing degrees of sensitivity with cell number and apoptosis 
complimenting each other. While HL60 and ML-1 cells had significant reduction in 
cell numbers and induction of apoptosis, U937 cells only had a mild response to 
Ara-C, with an initial small decrease in cell number but this recovered at the later 
time point with no apparent induction of apoptosis. This showed that HL60 and ML-
1 cell lines were more sensitive to Ara-C than U937, which appeared refractory to 
treatment.  
 
Cell cycle status across the different cell lines was similar showing a high 
frequency of cells in the cycling phases, which were slightly perturbed when adding 
Ara-C causing a small but insignificant block of cells within the S-phase. This 
shows that all cell lines should be incorporating Ara-C at comparable rates, even 
though as evidenced, they responded differently. However it can be noted that 
leukaemia cell lines by their very nature are highly proliferative due to their 
immortalisation and oncogenic status, meaning changes in cell cycle should be 
interpreted with caution.  
 
To resolve how leukaemic cell lines, with their similar cell cycle statuses could 
respond differently to Ara-C, induction of DNA damage was examined. As shown, 
all cell lines displayed initial increases in DNA damage by analysis of γH2AX and 
direct damage as measured by comet assay. By 96 hours in U937 and ML-1 cells 
this had began to fall, with HL60 cells continuing to increase their DNA damage 
after Ara-C exposure. It could be seen as well that there was an observable level of 
endogenous damage within the untreated condition. With such a low frequency of 
cells in G0, the cells are rapidly dividing causing potential replicative stress, which 
leads to genomic instability and activation of DNA response mechanisms (Hills and 




Diffley, 2014). This could also suggest that leukaemic cell lines have a tolerance to 
DNA damage, as they appear to bypass levels of endogenous damage in normal 
culture conditions. When using irradiation as a second form of DNA damage, again 
HL60 and ML-1 cells were shown to be more sensitive to DNA damaging 
treatments, and U937 cells were able to recover faster. Overall this showed that 
again there are differing responses between the cell lines to DNA damage, even 
when damage was inflicted by different methods.  
 
It is important to note that both HL60 and U937 cells possess mutant p53 with no 
levels of p53 protein (Sugimoto et al., 1992, Prokocimer et al., 1986) and ML-1 
cells are p53 wildtype (Smardova et al., 2005). p53 is a tumour suppressor and co-
ordinates responses to several cellular stresses, including DNA damage, and is 
one of the most commonly mutated proteins in oncogenic diseases. Typically, loss 
of p53 means that cells cannot co-ordinate an appropriate response to DNA 
damage. This means that where usually a p53 wildtype cell would undergo 
apoptosis in response to DNA damage, a p53 mutant would carry on proliferating 
regardless of damaged acquired (Muller and Vousden, 2013). Interestingly, only 
10% of AML patients appear to possess a mutant p53 (Trecca et al., 1994), in 
contrast to the majority of other cancers where p53 mutation rates are 
approximately 50% (Soussi et al., 2006). This would imply that HL60 and U937 
cells should behave in a similar manner post Ara-C treatment, as they have a 
similar p53 status, however the differences in responses to Ara-C shown must be 
due to other downstream mechanisms which are independent of p53.  
 
As DNA damage is induced upon Ara-C treatment in all the cell lines, it was next 
examined whether DNA repair could be a factor in the cell lines differing responses 
to Ara-C. While U937 and HL60 cells showed activation of NHEJ, ML-1 cells did 
not and none of the cell lines showed activation of HR repair. U937 cells had the 
highest level of activation of NHEJ repair appearing to correlate with their ability to 
maintain a refractory response to Ara-C treatment. Indeed it could have been 
expected that as the cell lines are highly proliferative and HR works as the cell is 
cycling, that this would have been the preferred method of repair (Mohrin et al., 
2010). However, NHEJ appears to be the preferred choice of DNA repair 
suggesting the cell lines may favour a quick fix over an accurate repair. Unusually, 




HL60 cells induced NHEJ post Ara-C treatment, contrary to its more sensitive 
phenotype, suggesting that U937 cells may have a more efficient, overactive repair 
mechanism. Moreover ML-1 cells displayed no indication of activation of DNA 
repair suggesting that overall they are preferentially led to apoptosis as evidenced 
by reduction in cell number and increase in AnnexinV staining. 
 
One future perspective would be to utilise the DNA repair reporter constructs 
developed to measure the efficiency and quality of the two DSB DNA repair 
mechanisms (Seluanov et al., 2010). Fluorescent reporter constructs, engineered 
for both HR and NHEJ activity, are linearised in vitro and transfected into cells. 
Successful re-joining and repair of the linearised construct allows for the 
expression of GFP and detection by flow cytometry, making this a very sensitive 
assay. Using these it would be extremely useful to observe and quantify any 
differences between the activity and rates of DNA repair between the cell lines. 
 
In summary this chapter shows that AML cell lines responses to Ara-C are 
heterogeneous. Although all cell lines display increase in DNA damage post Ara-C 
treatment, how they responded to treatment was diverse. 





Chapter 4. Results 2: Effect of Ara-C on Normal 
Cord Blood Haematopoietic Cells 
 
4.1 Introduction 
While understandably the majority of studies on chemotherapeutic drugs revolve 
around their effect on malignant cells, it is also of equal importance to assess their 
influence on normal tissues. As Ara-C is one of the most widely used drugs in the 
clinic for the treatment of AML there are a copious amount of studies into its effect 
on leukaemic cells. However, what is frequently understudied is how normal 
haematopoietic cells respond to Ara-C treatment. Particularly pertinent is the 
question: how do normal haematopoietic cells survive chemotherapeutic treatment 
to resurrect and maintain a normal haematopoiesis post therapy? While this 
question opens up numerous avenues to explore, regarding the results in Chapter 
3, it would be interesting to assess how normal haematopoietic cells respond to 
Ara-C regarding their DNA damage response and repair mechanisms.  
 
Recent years have seen a flurry of studies into the regulation of DNA damage in 
the HSC, with key findings showing that when comparing the HSC and progenitor 
populations they present differential responses to DNA damage by ionizing 
radiation (Milyavsky et al., 2010, Mohrin et al., 2010). While the murine system 
shows a preferential survival of HSC, with loss of progenitors, the opposite was 
shown to be true in the human HSC. Thus presenting remaining discrepancies 
between the murine and human systems as to which response to DNA damage 
entails.  
 
Hence it is of interest to investigate how Ara-C treatment may fit into the paradigm 
of what is already known about DNA damage response in the human 
haematopoietic system.  




For the study of the effect of Ara-C on normal primitive haematopoietic cells, 
material purified from umbilical cord blood (UCB) was utilized. UCB provides a 
cheap and abundant source of primitive material. Therefore, CD34+ cells purified 
from UBC blood were used as a comparison of both the in vitro and in vivo 
response of primitive haematopoietic stem and progenitor populations to Ara-C. 
  




4.2 Results – in vitro 
For in vitro analysis, CD34+ UCB cells were cultured on irradiated MS-5 stromal 
layers for at least 3 days before any treatment to allow sufficient time for recovery 
from thawing. As well, the use of stromal cells is essential in the long-term 
maintenance of primary haematopoietic cells for in vitro cultures. As outlined in the 
previous chapter, the in vitro experimental procedure for Ara-C treatment utilised a 
window of 24 and 96 hours exposure to Ara-C to enable an early and late time-
point of exposure.  
 
To compare HSC and progenitors, the populations were fractionated by way of flow 
cytometry as shown in Figure 4.1. Haematopoietic progenitor cells (HPCs) were 
defined as CD34+/CD38+ and haematopoietic stem and progenitor cells (HSPCs) 
as CD34+/CD38-. The HSPC population still remains a relatively heterogeneous 
population that can be further sub-fractionated into LT-HSC, ST-HSC and MPPs. 
However, it was necessary to have a primitive population with sufficient material 
available for analysis post chemotherapeutic treatment, so further refinement was 
not undertaken.  
 
Figure 4.1 FACS gating strategy for UCB stem and progenitor populations. 
Haematopoietic stem and progenitor populations (HSPC) (CD34+/CD38-) and 
haematopoietic progenitor populations (HPC) (CD34+/CD38+) FACS gates for in 
vitro cultures of CD34+ UCB cells on MS-5 stromal layers.  




4.2.1 Survival of normal CD34+ stem and progenitor populations post Ara-C 
treatment. 
After Ara-C exposure, HPC and HSPC population cell numbers were analysed by 
FACS (Figure 4.2A). Initially both populations showed a slight but insignificant 
reduction in cell numbers, which by 96 hours had decreased dramatically. The 
greatest effect could be seen in the HSPC population which had a 5-fold decrease 
compared to the HPCs, which displayed on average 3-fold reduction in cell number.  
 
Induction of apoptosis as demonstrated by AnnexinV staining was moderately 
increased across all populations (Figure 4.2B). HSPCs showed the most significant 
apoptosis at 24 hours (p=0.0065), which appears to precede the sizeable reduction 
in cell number at 96 hours. Evidence of apoptosis was still maintained in HSPC at 
96 hours (p=0.025). 
 
Figure 4.2 Cell counts and AnnexinV+ FACS analysis post Ara-C Treatment of 
CD34+ cord blood cells in vitro.  
(A) Fold change in cell number of HPCs (CD34+/CD38+) and HSPCs 
(CD34+CD38-) CB cells grown on MS-5 stromal cell layers 24 and 96 hours post 
Ara-C treatment in vitro compared to untreated as analysed by FACS (n=7) 
***p<0.0005, ****p<0.0001. Error bars are ± S.D. (B) Fold change of frequency of 
AnnexinV staining 24 and 96 post Ara-C treatment of CD34+ CD cells in vitro. 
*p<0.05, ** p<0.01 (n=4) error bars are ± S.D. 
 




Although there was slight increase in apoptosis in the HPCs, this was never able to 
reach significance. These results initially suggest that the more primitive HSPCs 
are more prone to the effect of Ara-C treatment than progenitor populations.  
 
This observation appears to go against what is inherently know about the nature of 
progenitor and stem cell populations concerning their cell cycle status. As the 
action of Ara-C relies on the cell entering the S-phase it would seem the most 
obvious scenario would be the proliferative progenitor populations would be most 


























4.2.2  Cell cycle status of stem and progenitor cells post Ara-C  
To compare the cell cycle status of the HSPC and HPCs cultured in vitro, cells 
were analysed by FACS for Ki67 and DAPI profiles. Both populations showed a 
relatively equal frequency of cells within G0, however HPCs had twice as many 
cells in the S/G2/M cycling phases compared to HSPCs (32% versus 15% 
respectively) (Figure 4.3) within the untreated condition.  
 
 
Figure 4.3 Cell cycle Ki67 intracellular staining in CD34+ cord blood cells in vitro 
post Ara-C. 
Analysis and quantification of cell cycle profiles of CD34+ populations HPC 
(CD34+/CD38+) and HSPC (CD34+/CD38-) in vitro 24 and 96 hours post Ara-C 
treatment by staining with Ki67 and DAPI for DNA content. Represented as 
frequency of cells. *p<0.05, **p<0.005, ***p<0.0005, ****p<0.0001 (n=4). Error bars 
are ± S.D. 





After 24 hours Ara-C treatment the most evident change was the significant 
enrichment in the frequency of cells within the resting G0 phase in both 
populations; HPCs doubled (p=0.03) and HSPCs almost tripled the amount of cells 
in G0 (p=0.001). In hand with this, there were significant reductions in the cycling 
phases, with HSPCs showing the most pronounced alterations. This suggests that 
when Ara-C is first added, any proliferating cells succumb rapidly to the treatment, 
initially sparing the more quiescent populations.  
 
However, by 96 hours, the scenario had changed quite dramatically in response to 
Ara-C. HPCs showed significant decreases in G1 (p=0.0009) and increases in S-
phase frequencies (p<0.0001), with only approximately 5% of cell within G0 
compared to untreated. HSPCs as well showed a reduced amount of quiescent 
cells, as compared to 24 hours Ara-C treated condition, but still retained 30% of 
cells within G0. Nonetheless, HSPCs still displayed the significant decrease in G1 
(p=0.0016) and increase in S-phase (p=0.09), seen in HPCs. As well, there was an 
almost complete abolishment of G2/M phase within HSPCs (p=0.018).  
 
At the early time point of treatment it is evident that there is enrichment of cells in 
G0 across the populations as Ara-C takes its first effects. However at the later time 
point, when cells were exiting quiescence to continue cycling, there was an 
apparent blocking of cells within the S-phase as previously described by van Pelt et 
al. and previously shown in the AML cell lines treated with Ara-C (Chapter 3). This 








4.2.3  DNA damage is induced by Ara-C in normal CD34+ stem and 
progenitor cells 
Previously in this study it was shown that Ara-C induces DNA damage in AML cell 
lines so it stands to reason that Ara-C is also inflicting damage upon normal 
haematopoietic cells in vitro. CD34+ cells were cultured on MS-5 stromal layers 
and treated with Ara-C 500 nM before analysis of DNA damage, by measuring the 
phosphorylation of H2AX by FACS, 24 and 96 hours post treatment (Figure 4.4A).  
 
 
Figure 4.4 Levels of γH2AX measured by intracellular FACS post Ara-C treatment 
in CD34+ in vitro. 
(A) Representative histogram of phospho-flow cytometry for intracellular staining of 
γH2AX in CD34+ CB cells in vitro grown on MS-5 stromal cell layers under 
conditions stated. (B) Quantification of γH2AX by fold difference of MFI by 
geometric mean normalized to untreated. CD34+ CB were cultured in presence of 
Ara-C 500 nM or untreated condition and analyzed at 24 and 96 hours post 
treatment by FACS. **p<0.01, ***p<0.0005 (n=8). Error bars are ± S.D. 
 
All CD34+ populations displayed significant increases in γH2AX post Ara-C 
treatment (Figure 4.4B). HPCs showed initially, at 24 hours, a 4-fold increase in 




damage which further increased to 6-fold at 96 hours. On the other hand, HSPCs 
showed only a 2-fold increase in γH2AX at 24 hours, with this doubling by 96 hours. 
As could be anticipated, HPC gained more DNA damage from Ara-C than HSPC, 
which is comparable to their proliferation statuses, with progenitors cycling more 
than stem populations (Figure 4.3).  
 
As performed previously on the AML cell lines, visualization of γH2AX nuclear foci 
by immunofluorescence (IF) was used as a more qualitative way to quantify DNA 
damage (Figure 4.5A). HSPCs and HPCs were sorted from MS-5 stromal layers 24 
hours and 96 hours post Ara-C treatment. Foci were scored as described 
previously (0 foci = undamaged, 1-4 = increasingly damaged and >4 = very 
damaged).  






Figure 4.5 Foci counts of γH2AX post Ara-C treatment in CD34+ cells in vitro. 
(A) Representative immunofluorescence staining of γH2AX foci (green) and DNA 
(blue) by DAPI in CD34+ CB HSPC and HPC populations post Ara-C treatment 
grown on MS-5 stromal cell layers in vitro. Scale bar, 10 µm. (B) Quantification of 
number of foci per cell represented as frequency of cells with either 0, 1-4 or >4.foci 
per cell. 100 cells were counted per condition **p<0.01 (n=4). Error bars are ± S.D. 
 
By this method all samples showed increased numbers of γH2AX foci in the Ara-C 
treated condition (Figure 4.5B). 50% of HPCs showed a significant amount of 
γH2AX displaying 1-4 foci/nucleus at 96 hours (**p=0.007) and >4 foci/nucleus 
(p=0.05). The effect on HSPCs was milder, with no significant changes and small 
increases in nuclear foci counts. While the onset of DNA damage by Ara-C was not 




as marked when quantifying by foci counts, it showed a similar trend to γH2AX 
FACS, which measures overall intensity.  
 
To define if there was indeed direct DNA damage, using the same in vitro 
procedure, HPCs and HSPCs were sorted from MS-5 stromal layers for analysis by 
alkaline comet assay (Figure 4.6). HPCs showed a significant increase in olive tail 
moment at 96 hours (p=0.024) post Ara-C treatment, comparable to γH2AX IF data 
(Figure 4.5B). Unusually, 24 hours post Ara-C treatment HSPC showed significant 
increases in olive tail moment (p=0.035) with no changes compared to untreated at 





Figure 4.6 Alkaline comet assay of CD34+ cells treated with Ara-C in vitro.  
Quantification of direct damage by olive tail moment, a measurement of DNA tail 
migration x comet tail DNA density. CD34+ HSPC and HPC populations were 
sorted from MS-5 stromal layers at 24 and 96 hours post Ara-C 500nM treatment in 
vitro. 100 cells were scored per slide where possible. *p<0.05 (n=2). Error bars (in 
red) are ± S.D.  
 
Overall there is evidence for generation of DNA damage by treatment with Ara-C in 
normal CD34+ stem and progenitor populations. DNA damage is inflicted at a 
greater rate in HPCs, which correlates with their increased proliferation compared 
to HSPCs.  




4.2.4 Activation of DNA repair mechanism post Ara-C treatment 
In Chapter 3 it was shown that AML cell lines were able to initiate DNA repair 
mechanism in response to Ara-C treatment (Section 3.2.9). To investigate whether 
the same holds true for normal CD34+ populations, IF staining was performed for 
the nuclear localisation of 53BP1 and RAD51 (Figure 4.7A and 4.8A) for analysis of 
NHEJ and HR repair respectively. 
 
 
Figure 4.7 Foci counts of 53BP1 in CD34+ cells post Ara-C treatment in vitro. 
(A) Representative immunofluorescence staining of 53BP1 foci (green) and DNA 
(blue) by DAPI in CD34+ CB HSPC and HPC populations post Ara-C treatment 
grown on MS-5 stromal cell layers in vitro. Scale bar, 10 µm. (B) Quantification of 
number of foci per cell represented as frequency of cells with either 0, 1-4 or >4.foci 
per cell. 100 cells were counted per condition (n=3). Error bars are ± S.D. 





HPCs and HSPCs both showed increases in number of 53BP1 nuclear foci (Figure 
4.7B). Again it can be seen that HSPCs display a weakened response to Ara-C 




Figure 4.8 Foci counts of RAD51 in CD34+ cells post Ara-C treatment in vitro. 
(A) Representative immunofluorescence staining of RAD51 foci (green) and DNA 
(blue) by DAPI in CD34+ CB HSPC and HPC populations post Ara-C treatment 
grown on MS-5 stromal cell layers in vitro. Scale bar, 10 µm (B) Quantification of 
number of foci per cell represented as frequency of cells with either 0, 1-4 or >4.foci 
per cell. 100 cells were counted per condition (n=3). Error bars are ± S.D. 
 
 




On the other hand, nuclear foci formation of RAD51 was barely detected in 
response to Ara-C treatment (Figure 4.8B), especially in HSPCs. Only HPCs at 24 
hours post Ara-C treatment showed a slight increase in number of cells displaying 
HR repair, most likely due to HR only being active in the cycling phase of the cell 
cycle.  
 
Overall it appears that in the face of DNA damage by Ara-C normal human CD34+ 
populations will activate their repair mechanism, in a small frequency of cells, with 
a preference for NHEJ repair mechanism.  
 
 
4.2.5 Response of normal CD34+ cells to DNA damage by irradiation. 
It appears that although HSPC as a population receives less DNA damage from 
Ara-C over all than compared to HPC population, nevertheless HSPCs displayed a 
greater fold reduction in cell number and increase in apoptosis (Figure 4.2), 
suggesting that human stem containing populations are more sensitive to DNA 
damage than progenitors. Indeed, this similar finding was observed by Milyavsky et 
al. when using irradiation on human cord blood (Milyavsky et al., 2010). To test if 
DNA damage from irradiation reflected what was observed in our system with Ara-
C, and was consistent with the literature, CD34+ CB cells were cultured on MS-5 
stromal layers before irradiation with 2 Gy and analysed up to 48 hours later.  
 
Analysis of cell number by FACS saw significant and comparable fold reductions of 
both HPCs and HSPCs, starting at 24 hours post irradiation and continuing to 
decrease with an approximate a 5-fold reduction in both populations by 48 hours 
(Figure 4.9A).  
 
Although there appeared to be no differences in rate of decline of cell numbers 
between HSPCs and HPCs after treatment with irradiation, there were however 
evident differences in apoptosis (Figure 4.9B). Analysis of AnnexinV by 8 hours 
post irradiation in HPCs showed a slight increase but no significant induction of 
apoptosis (p=0.15), whereas HSPCs at the same time point had a 5-fold increase 
in apoptosis (p=0.005). Even beyond 8 hours, HSPCs maintained a significant  





Figure 4.9 Response of CD34+ cells to DNA damage by irradiation. 
CD34+ CB cells were grown in vitro on MS-5 stromal layers, irradiated with 2 Gy 
and analysed at 0, 2, 4, 8, 24 and 48 hours post irradiation. All results are 
represented as fold change compared to untreated. (A) Absolute cell counts by 
FACS (n=3) (B) Frequency of AnnexinV+ cells (n=3) (C) Intracellular FACS staining 
for γH2AX (n=3). *p<0.05, **p<0.005, ***p<0.0005, ****p<0.0001. Error bars are ± 
S.D.   
 
AnnexinV expression (48 hours p=0.02), compared to HPCs, which throughout only 
maintained an approximate 2-fold increase in AnnexinV expression.  
 
Invariably, as HSPCs demonstrated higher apoptosis than HPCs after irradiation, 
HSPCs showed a 11-fold increase in DNA damage by γH2AX compared with 
HPCs at 2 hours, which only had a 6-fold increase, nearly half of that of the HSPCs 




(Figure 4.9C). Although the timing of apoptosis did not directly correlate with the 
γH2AX levels, indeed these findings were similar to what Milyavsky et al. reported. 
In that although most DNA damage was resolved in between the 8 and 24 hour 
time points in both populations, there was still a marked and persistent apoptosis in 
the remaining more primitive HSPC compartment. Showing an increased 
intolerance to DNA damage in the more primitive HSPCs. 
 
Overall it appears that any DNA damaged incurred, be it through Ara-C or 
irradiation, HSPC populations are less able to tolerate the damage and can 
hypothetically be deemed more sensitive.  
 




4.3 Results – in vivo 
While in vitro assays are an extremely useful and straightforward tool for 
experiments involving drug treatments, for a more physiological setting, use of the 
xenograft model is routinely used in the study of human haematopoiesis. The 
mouse bone marrow provides an enhanced microenvironment for long-term 
maintenance of the HSPCs, with a full array of niche components for proper 
regulation of the primitive cells. Whereas the 2-D culture system, with MS-5 stromal 
layers, provides support, but not a full physiological maintenance of the HSPCs.  
 
Therefore to examine response of Ara-C to normal human HPCs and HSPCs in 
vivo, sub-lethally irradiated NSG mice were injected intravenously with human 
CD34+ cells, left to engraft for 12 weeks, before treatment with Ara-C as outlined in 
Figure 4.10.  
 
 
Figure 4.10 Schematic of in vivo Ara-C treatment protocol. 
NSG mice were transplanted with 50,000 CD34+ purified cord blood cells. 
Engraftment was analysed at 12 weeks before treatment with 10mg/kg per day for 
7 days. A cohort of mice were sacrificed 24 hours post the final injection and 
another cohort 7 days post the final injection after a recovery period.  
 
 
To maintain clinical relevance a dose regime of 10 mg/kg Ara-C for 7 consecutive 
days was administered (Robles et al., 2000). This imitates a low-dose regime often 




used to treat older patients to reduce toxicity. Mice were sacrificed 24 hours and 7 
days post final injection for early and late time points of analysis.  
 
4.3.1 Ara-C causes reduction in human engraftment. 
Following Ara-C treatment of CD34+ engrafted NSG mice, human bone marrow 
chimerism was analysed by assessing the frequency of expression of hCD45 in the 
total CD45 fraction of the murine bone marrow (Figure 4.11A). Significant 
decreases in human CD45 engraftment could be seen at 24 hours; with further 
significant reductions 7 days post Ara-C treatment, showing the diminishing effect 




Figure 4.11 Human CD45+ cells response to Ara-C treatment in vivo. 
(A) Analysis of human engraftment at 24 hours and 7 days post final Ara-C 
treatment by measuring frequency of hCD45+ expressing cells by FACS within the 
total CD45+ fraction of the murine bone marrow (hCD45+/mCD45+). Median bars 
are shown. (B) Fold change response of the frequency of human CD45+ cells 
within the murine bone marrow to Ara-C treatment. *p<0.05, **p<0.005, 
***p<0.0005 (n=5).  
 
Indeed there are significant fold reductions in the frequencies of human cells 
compared to murine within the bone marrow at both 24 hours and 7 days (Figure 
4.11B), showing a significant response of the human cells to Ara-C treatment.  




4.3.2 Normal stem and progenitor cell numbers are reduced by Ara-C 
treatment. 
While there is significant reduction in frequency of human cells by examination of 
the whole CD45+ haematopoietic populations after Ara-C treatment, a closer 
analysis of actual cell numbers is needed. Observing specific populations within the 
bone marrow will determine if one population is more affected from Ara-C treatment 




Figure 4.12 Cell counts of total bone marrow and human cells in vivo post Ara-C 
treatment. 
FACS analysis of absolute cell counts post Ara-C treatment in vivo. Data is 
represented as fold change compared to untreated. (A) Cell counts of the total 
bone marrow. (B) Cell counts of the human CD45+ population. (C) Cell counts of 
HPCs (CD34+/CD38+) and HSPCs (CD34+/CD38-). *p<0.05, **p<0.005, 
****p<0.0001 (n=3). Error bars are ± S.D. 
 




Analysis of the total bone marrow by FACs showed a significant (p=0.04) two-fold 
reduction in cellularity at 24 hours, which began to rise slightly by 7 days (Figure 
4.12A). The reductions in cell numbers were more marked when examining the 
total human CD45+ fraction of cells, which displayed a significant 3-fold reduction; 
this was maintained up to 7 days post Ara-C treatment (Figure 4.12B). This 
suggests the haematopoietic compartment is more sensitive to the effect of Ara-C 
than other bone marrow populations.  
 
Indeed this observation was even more exacerbated when analysis of the more 
primitive haematopoietic populations showed that Ara-C treatment incurred a 10-
fold reduction in HPC cell number compared to 4-fold in HSPC at 24 hours (Figure 
4.12C). 7 days after the final treatment, there were still significant reductions in cell 
numbers for both populations, however there was evidence that the cells had 
begun to regenerate as the fold reduction was not as marked compared to 24 
hours. 
  




Analysis of AnnexinV showed a significant 2-fold increase in apoptosis of HPC 
populations (p=0.001) at 24 hours (Figure 4.13), corresponding to the greater 
reduction in cell number observed. At 7 days apoptosis was still observed in HPCs 
(p=0.053). Unusually, HSPCs did not show any significant increase in apoptosis at 




Figure 4.13 Apoptosis analysis by AnnexinV+ staining of CD34+ cells in vivo 
post Ara-C treatment.  
Analysis of apoptosis by AnnexinV staining by FACS of HSPCs (CD34+/CD38-) 
and HPCs (CD34+/CD38+) post Ara-C treatment in vivo. Data is represented as 
fold change compared to mean of the untreated. **p<0.01 (n=3). Error bars are ± 
S.D. 
 




4.3.3 Ara-C causes changes in cell cycle of progenitors in vivo.  
Analysis of cell cycle status of CD34+ populations in vivo was undertaken by 
examining Ki67 and DAPI profiles. HPCs and HSPCs were both shown to have 
approximately 40% of cells within G0 in the untreated condition (Figure 4.14).  
 
Remarkably HSPCs appeared to show no perturbations in cell cycle at 24 hours 
post Ara-C treatment, seemingly contrary to the cell loss observed. HPCs however, 
showed a significant decrease in frequency of cells in G0 (p=0.02) and a significant 





Figure 4.14 Analysis of cell cycle by intracellular FACS of Ki67 in CD34+ cells in 
vivo post Ara-C treatment. 
Analysis of cell cycle by FACS of Ki67 and DAPI stained HSPCs (CD34+/CD38-) 
and HPCs (CD34+/CD38+) cells post Ara-C treatment in vivo. Represented as 
frequency of cells. *p<0.05, **p<0.01. Error bars are ± S.D. 
 




4.3.4 DNA Damage post Ara-C treatment in vivo. 
Considering the HSPC population appeared to endure a cell loss without 
alterations in cell cycle in response to Ara-C treatment in vivo, as compared to HPC, 
assessment of DNA damage was utilised post-treatment to determine whether Ara-
C is acting sufficiently upon the different populations.  
 
Assessment of DNA damage by γH2AX using FACS showed both HPCs and 
HSPCs increased levels of γH2AX at 24 hours post Ara-C treatment (Figure 4.15A).  
 
Figure 4.15 Quantification of γH2AX in CD34+ cells by FACS and IF post Ara-C 
treatment.  
(A) Quantification of γH2AX by fold difference of MFI by geometric mean 
normalized to mean of the untreated condition. CD34+ cells were engrafted in vivo 
and analysed at 24 hours post-final Ara-C treatment. *p<0.05, (n=3). Error bars are 
± S.D. (B) Immunofluorescence staining of γH2AX staining 24 hours post final Ara-
C treatment in vivo. Quantification of number of foci per cell represented as 
frequency of cells with either 0, 1-4 or >4.foci per cell. 100 cells were counted per 
condition (n=3). Error bars are ± S.D. 




HPC showed a 4-fold, yet statistically insignificant increase (p=0.07) and HSPC 
showed 2-fold induction of γH2AX (p=0.017). When γH2AX foci were quantified by 
IF, there seemed to be a slight increases in DNA damage in both populations 
(Figure 4.15B).  
 
Measurement of direct DNA damage by alkaline comet assay showed significant 
increases in olive tail moment in HPC (Figure 4.16A), however HSPC appeared to 
display no differences in DNA damage post Ara-C treatment (Figure 4.16B). 
 
 
Figure 4.16 Alkaline comet assay of CD34+ cells treated with Ara-C in vivo.  
Quantification of direct damage by olive tail moment, a measurement of DNA tail 
migration x comet tail DNA density. (A) HPC (CD34+/CD38+) and (B) HSPC 
(CD34+/CD38-) populations were sorted from CD34+ engrafted NSG mice at 24 
hours and 7 days post Ara-C treatment in vivo. 100 cells were scored per slide 
where possible. *p<0.05 (n=3). Error bars are ± S.D.  
 
HPC populations behaved as expected in response to Ara-C treatment in vivo, 
showing reduction in cell numbers; increase in frequency of cells in S-phase and 
increases in DNA damage. However, HSPC populations although showing a 
significant reduction in cell number, displayed no apoptosis or adaptations of cell 
cycle status with slight evidence of DNA damage by γH2AX. This perhaps suggests 
that any HSPC that come into contact with Ara-C die at a quicker rate and are lost 
before detection, whereas HPC are able to persist longer with damage. HSPC 
numbers were then able to revive after the 7-day recovery as Ara-C is cleared from 
the system.  




4.3.5 DNA repair post Ara-C treatment in vivo.  
As seen in vitro normal haematopoietic cells are able to show evidence of initiation 
of DNA repair mechanisms in response to Ara-C. Again, using IF staining for 
nuclear localisation of 53BP1 and RAD51, there was almost undetectable evidence 
of DNA repair by either mechanisms in both HSPCs and HPCs (Figure 4.17).  
 
 
Figure 4.17 Analysis of DNA Repair by NHEJ and RAD51 in CD34+ treated with 
Ara-C in vivo.  
Immunofluorescence staining of (A) 53BP1 nuclear foci and (B) RAD51 nuclear foci 
24 hours and 7 days post final Ara-C treatment in vivo. Quantification of number of 
foci per cell represented as frequency of cells with either 0, 1-4 or >4.foci per cell. 
100 cells were counted per condition (n=3). Error bars are ± S.D. 
 
  





In this chapter the effect of chemotherapeutic treatment by Ara-C was determined 
on normal haematopoietic cells. Using the in vitro model it was shown that HSPCs 
had a greater fold reduction in cell numbers, compared to HPCs, as well as a 
higher induction of apoptosis in response to Ara-C. However, as described 
previously, Ara-C works by incorporating into proliferating cells and analysis of cell 
cycle status showed that HPCs had a greater frequency of cells within the cycling 
phases. This suggested that HPCs should be the most effected. Indeed, when DNA 
damage was assessed it was shown that HPC had a greater amount of DNA 
damage in response to Ara-C when compared to HSPC. Taking this into 
consideration, even though HPCs are cycling more than HSPCs in vitro, thus 
receiving more DNA damage from Ara-C, HPCs appear to be more tolerant of Ara-
C treatment than HSPCs. As well, analysis of activation of DNA repair mechanisms 
showed a greater frequency of HPCs with 53BP1 localisation, consistent to the 
amount of damage incurred. Interestingly, CD34+ CB cells showed a preference for 
NHEJ repair post Ara-C treatment, as also evidenced in the last chapter with AML 
cell lines. 
 
While in vitro assessments of drug treatments are extremely useful, in the human 
haematopoietic field in vivo analysis using the xenograft model is the gold standard. 
After engrafting mice with CD34+ CB cells and treating with Ara-C there was 
reduction in human engraftment in the mouse bone marrow. When observing 
actual cell numbers of HPCs and HSPCs it was shown that HPCs had a greater 
fold reduction than HSPCs, coupled with a higher induction of apoptosis after Ara-C 
treatment. Paired with this, a perturbation in the cell cycle of HPCs was also 
observed. However the cell cycle of HSPCs remaining unchanged, as the majority 
of HSPCs were in the G0/G1 phases of the cell cycle, allowing greater evasion of 
the action of Ara-C. HPCs also showed a higher degree of DNA damage post Ara-
C. However, contrary to what has previously been shown in vitro, there appeared to 
be no activation of DNA repair mechanisms in response to Ara-C in either HPCs or 
HSPCs. This could be due to the differences in the time points analysed and doses 
of Ara-C used. 
 




The comparison of in vitro and in vivo data however should be taken with some 
caution. As alluded previously, the physiological interactions governing the 
regulation of the haematopoietic cells in both models is vastly different. It is known 
that the bone marrow niche is comprised of many different compartments of cells 
such as mesenchymal, osteoblastic and endothelial cells, each playing their own 
role in maintenance of the HSC in vivo (Morrison and Scadden, 2014). As well, the 
different dosages and treatment regimes of Ara-C used makes the direct 
comparison between the models even more difficult. In vitro, Ara-C is exposed 
directly to the haematopoietic cells and is added in a single dose. When the cells 
are analysed 96 hours later, Ara-C is still within the system, as the effect of the 
drug is more exacerbated than the early 24-hour time point. Whereas in vivo, Ara-C 
is dosed over several days into a full biological system where the drug has more 
boundaries to cross before reaching the bone marrow and taking its effect. By 7 
days post the final treatment; most of the Ara-C appears to have cleared from the 
system as cell numbers show signs of recovery, with reductions in apoptosis. 
Therefore it was understandable that although there are differences in the models 
used and the observed outcomes, valuable insights can still be gained about the 
effect of Ara-C on normal CD34+ cells from in vitro and in vivo analysis.  
 
One of the more pronounced changes that Ara-C inflicted was in the cell cycle. In 
vitro there was an initial enrichment of both HPCs and HSPCs cells within G0 at 24 
hours post Ara-C treatment. This suggested that any cells in cycle when Ara-C was 
added were cleared by the treatment relatively quickly. By 96 hours however, cells 
that had come out of G0 and into cycle and were enriched in the S-phase 
compared to untreated. This was most pronounced in HPCs, whereas HSPCs 
seemed to be slower to exit quiescence and there was a substantial decrease in 
G2/M phase cells, showing they were unable to get passed the S-phase, 
suggestive of an S-phase block after long-term exposure to Ara-C and induction of 
DNA damage. The same could be seen in vivo in the HPC population. However 
HSPCs in vivo showed no observable differences in cell cycle post Ara-C, with 
most of the cells staying in G0/G1. To assess if this was indeed a true arrest at the 
G1/S-phase, molecular characterisation of levels of p21CIP1 (encoded by CDKN1A) 
(Niculescu et al., 1998) and Cyclin E (Ohtsubo et al., 1995), as well as the analysis 
of activation of p53 (Meek, 2009) would be useful to dissect the cell fate decisions 




happening between HPCs and HSPCs in response to DNA damage inflicted by 
Ara-C.  
 
Overall, it could be suggested that in the treatment of HPCs and HSPCs with Ara-C, 
they show different dynamics of response. In vitro analysis shows that when 
CD34+ cells do come into contact with Ara-C they incur DNA damage and initiate 
NHEJ repair. However HSPCs appear to perish more readily, whereas HPCs are 
blocked in G1/S-phase arrest seeming to tolerate the effect of Ara-C longer. On the 
other hand, the in vivo analysis provides a bigger picture in what could be 
happening clinically. As Ara-C treatment comes to an end, the quiescent HSPCs 
have been spared and they remain to help regenerate the bone marrow.  




Chapter 5. Results 3: DNA Damage response of 




The DNA damage response (DDR) in normal human haematopoiesis still remains 
somewhat controversial. Yet currently, perhaps more is known about the DNA 
damage and repair mechanisms in AML, due to their role in pathogenesis of the 
disease and responses to therapies. While mutations in DNA damage response 
and repair genes are rare in AML (CancerGenomeAtlasResearch, 2013), it is 
apparent that the many epigenetic abnormalities observed in AML, can cause 
deregulation of the gene expression of the many DDR genes. Briefly, this can 
range from certain complex karyotype AMLs overexpressing genes such as RAD21 
and MSH6 (Schoch et al., 2005) causing enhanced DNA repair activity by HR or 
MMR respectively. In addition, fusion onco-proteins, such as PML-RARA, can 
inhibit the expression of numerous DNA repair genes including DNA-PK involved in 
NHEJ repair (Casorelli et al., 2006). These alterations in DDR are heterogeneous, 
as is the very nature of AML, often depending on their karyotype and gene 
mutations.  
  
Previously in this study it was shown that when normal haematopoietic cells come 
into contact with Ara-C, DNA damage is incurred and NHEJ repair is activated in 
both HSPCs and HPCs. However, the more mature progenitor populations 
appeared to be more tolerant of the Ara-C treatment. The literature certainly shows 
that there are differences in the DNA damage responses between progenitor and 
stem cell populations. Therefore could the same be said for AML when comparing 
LICs and bulk tumour populations? The final part of this study will be to ascertain 
the response of primary human AML samples to treatment with Ara-C, again with 
key focus on activation of DNA damage and repair mechanisms. 
 





For this investigation a panel of six primary AML patient samples was selected 
based on their ability to engraft into NSG mice. From the clinical data available 
there was a mixture of karyotypes, however most patient samples that are able to 
engraft come with a intermediate to poor risk group (Table 1). Although requested, 
clinical outcome data for the samples was unattainable at the on going time of the 
study. All samples were negative for NPM1 mutation (Taussig et al., 2010).  
 
 Karyotype/FAB Subtype Risk Group 
AML1  M0 - Inv(3)(q21;q26)t(8;13) Poor 
AML2  Normal Intermediate 
AML3  Normal - FLT3-ITD Intermediate 
AML4  M5 – t(9;11)(p21q23) MLL/AF9 Intermediate 
AML5  M1 Intermediate 
AML6  N/A N/A 
Table 5.1 Karyotypes and risk groups of the cohort of primary AML patient 
samples. 
 
To provide the best comparison to normal haematopoiesis, only CD34 expressing 
AML samples were used, where pre-screening had been done to determine that 
LICs were within the CD34+ compartment. AML6 was the only sample where LICs 
were undetermined therefore it can be said that LICs are highly enriched, but 
perhaps not exclusively, within the CD34+ compartment (Taussig et al., 2008). 
 
Samples were injected i.v. and when high engraftment (~80% hCD45) was attained 
Ara-C was administered as described previously (Chapter 4), 10mg/kg daily for 7 
days. Again, samples were analysed at 24 hours and 7 days post the final injection. 
As seen in Figure 5.1 the phenotypic expression of CD34 and CD38 post 
engraftment is diverse across the samples and to assure that a leukaemic 
engraftment was obtained expression of CD33 versus CD19 was always assessed. 
For this study CD34+ and CD34- populations were analysed separately to 
correspond with LIC containing and bulk tumour populations respectively.  





Figure 5.1 Phenotypic profiles of primary AML patient samples. 
FACS plots showing the expression profiles of CD34/CD38 and CD33/CD19 (gated 
from total CD45) post engraftment for the cohort of primary AML patient samples. 
 




5.2.1 Effect of Ara-C on AML CD45 engraftment in vivo. 
Following Ara-C treatment of AML engrafted mice, human bone marrow chimerism 
was analysed by assessing the frequency of human CD45 expression in the total 
CD45 fraction of the murine bone marrow (Figure 5.2). Significant decreases in 
AML engraftment were seen at 24 hours post Ara-C treatment in 50% of the 
samples (AML1 p=0.002, AML2 p=0.03 and AML3 p=0.006). Human engraftment 
was even further diminished at 7 days, for samples AML2 (p=0.006) and AML3 
(p=0.0002). There was no data for sample AML1 at the 7-day time point due to the 
aggressiveness of the leukaemia sample weakening the animals and causing 
premature death after challenge from Ara-C. Frequency of AML engraftment for 
samples AML4 and AML6 however remained relatively unchanged.  
 
 
Figure 5.2 Human CD45+ engraftment of primary AML samples post Ara-C 
treatment. 
Analysis of human engraftment at 24 and 7 days post final Ara-C treatment by 
measuring frequency of hCD45+ expressing cells by FACS within the total CD45 
fraction of the murine bone marrow. *p<0.05, **p<0.005, ***p<0.0005. Error bars are ± 








5.2.2 Reduction in the number of AML cells post Ara-C treatment in vivo.  
As there were differences in the reduction of engraftment between AML samples 
an examination of actual cell numbers was undertaken to ascertain whether CD34+ 
populations, compared to CD34- were more affected by the Ara-C treatment.  
 
 
Figure 5.3 Cell counts of human AML cells in vivo post Ara-C treatment. 
FACS analysis of cell counts of (A) CD34+ and (B) CD34- populations post Ara-C 
treatment in vivo. Data is represented as fold change compared to mean of untreated 
samples. *p<0.05, **p<0.005, ***p<0.001, ****p<0.0001. Error bars are ± S.D (n=3-6 
mice). 
 
CD34+ LIC containing populations showed a dramatic fold reduction in the number 
of cells at 24 hours post Ara-C treatment compared to untreated, with all but 
sample AML4 showing a significant decline in numbers (Figure 5.3A). By 7 days 




there was evidence of recovery of cell numbers in samples AML2 and AML6 
however samples AML3 and AML5 appeared to decline even further.  
 
The CD34- populations at 24 hours, although showing hugely significant reductions, 
they were not as marked at the corresponding CD34+ populations (Figure 5.3B). 
CD34+ populations of sample AML1 were decreased by approximately 100-fold in 
response to Ara-C, whereas CD34- populations were only reduced 10-fold. Another 
example is sample AML6, where the CD34+ population was reduced on average 
25-fold and the CD34- population 14-fold. The only sample to buck this trend was 
AML4, which showed a significant reduction in CD34- cell numbers (p=0.0007) by 
5-fold compared to untreated, whereas the CD34+ population was approximately 
1.5-fold reduced. By 7 days post Ara-C treatment 50% of the samples appeared to 
have regained numbers of CD34- cells back to levels comparable with untreated. 
While samples AML3 and AML5 again showed further declines in cell number.  
 
Ara-C was extremely effective on the majority of samples, with sample AML4 being 
the least responsive to treatment. Sample AML3 was particularly sensitive being 
almost completely diminished with no recovery at 7 days. Overall the samples 
showed a mixed response to treatment, with CD34- populations showing the lowest 
reduction in cell number and the quickest recovery by 7 days post Ara-C treatment.  
 
5.2.3 Induction of apoptosis by Ara-C treatment of AML samples in vivo.  
Analysis of apoptosis was done by staining for AnnexinV expression post Ara-C 
treatment in vivo. Analogous with the reduction in cell numbers, CD34+ populations 
showed greater fold-increases in apoptosis than compared to CD34- populations 
from the same samples (Figure 5.4A). Sample AML3 had a 5-fold increase in 
apoptosis in CD34+ cells (p=0.0001), yet only a 2.5-fold increase in CD34- cells 
(p=0.002) at 24 hours.  





Figure 5.4 Apoptosis analysis by AnnexinV+ staining of primary AML samples in 
vivo post Ara-C treatment. 
Analysis of apoptosis by AnnexinV staining by FACS of (A) CD34+ and (B) CD34- 
fractions post Ara-C treatment in vivo. Data is represented of fold change compared to 
mean of untreated. *p<0.05, **p<0.005, ***p<0.0005, ****p<0.0001. Error bars are ± 
S.D. (n=3-6 mice). 
 
By 7 days most CD34+ populations had reduced apoptosis compared to 24 hours, 
yet there was still evidence of significant differences compared to untreated. Only 
sample AML5 maintained the same frequency of AnnexinV positive cells, 
comparable to the further reductions in cell number seen at 7 days for this sample.  
 
CD34- populations by 7 days post Ara-C treatment as well showed levels of 
apoptosis beginning to return to that of untreated, yet still had significant 




frequencies of cells staining for AnnexinV (Figure 5.4B). Sample AML4 was the 
only samples that had completely reduced its apoptosis by 7 days post Ara-C 
treatment, again showing a quick recovery.  
 
5.2.4 Cell cycle status of AML patents samples post Ara-C treatment in vivo.  
To investigate if the differences in reduction of cell numbers and apoptosis 
observed correlated with proliferation status, analysis of the cell cycle status of 
CD34+ and CD34- AML populations was undertaken by examining Ki67 and DAPI 
profiles by FACS.  
 
As evidenced in Figure 5.5, the frequency of the cell cycle phases between each of 
the samples at the untreated level is vastly different. Especially when comparing 
the frequency of G0 cells in samples AML4 and AML5 which are 40% and 80% 
respectively. At 24 hours post Ara-C treatment samples AML3 and AML5 show 
significant enrichment of G0 cells in both CD34+ and CD34- populations. This G0 
enrichment was continued up to 7 days, with sample AML5 as well showing 
significant reductions in the S and G2/M cycling phases. Sample AML6, and 
partially sample AML2, showed the stalling of cells at the G1/S phases in response 
to Ara-C treatment in both CD34 populations over both the time points analysed. 
Sample AML4 did not appear to react to the treatment of Ara-C.  
 
Overall CD34- populations had a greater proportion of cells within G0, comparable 
to their lower reduction in cell numbers and lower induction of apoptosis compared 
to CD34+ populations. As well there was a mixture of responses with some 
samples stalling in the cycling phases and other samples enriching for G0 cells.  





Figure 5.5 Cell cycle profiles by Ki67 staining of AML patient samples post Ara-C 
treatment in vivo. 
Analysis of cell cycle by FACS of Ki67 and DAPI intracellularly stained primary AML 
patient samples in vivo. CD34+ and CD34- populations are represented as frequency 
of cells within the cell cycle phases. *p<0.05, **p<0.005, ***p<0.0005, ****p<0.0001. 
Error bars are ± S.D (n=3-6 mice). 





5.2.5 DNA Damage post Ara-C in primary AML samples in vivo. 
As CD34+ cells were shown to be more proliferative and effected by Ara-C in vivo 
than CD34- populations, assessment of DNA damage was employed to determine 
whether the AML samples were being sufficiently exposed to the drug. Overall 
levels of γH2AX by FACS showed mild differences post Ara-C treatment compared 
to untreated (Figure 5.6) in both CD34 populations. 
 
Figure 5.6 Analysis of DNA damage by γH2AX FACS in primary AML patient 
samples post Ara-C treatment. 
Quantification of γH2AX by fold difference of MFI by geometric mean normalised to the 
mean of the untreated condition. Cells analysed 24 and 7 days after the final dose of 
Ara-C and were fractioned into CD34+ and CD34- populations. *p<0.05, **p<0.005. 
Error bars are ± S.D (n=3-6 mice). 





Comparing CD34+ (Figure 5.6A) and CD34- (Figure 5.6B) populations between the 
same samples showed comparable changes in fold-change of γH2AX, with all 
samples at 7 days post Ara-C treatment displaying reduced levels of DNA damage. 
Interestingly, samples AML1, AML5 and AML6 showed increases in DNA damage, 
yet samples AML2, AML3 and AML4 all showed decreases across both the CD34 
populations analysed. 
 
When γH2AX was quantified by foci counting (Figure 5.7A) at 24 hours final 
treatment, again there was only evidence of mild changes in the level of DNA 
damage in the majority of samples (Figure 5.7B) after Ara-C treatment. Analysis of 
the CD34+ for sample AML5 could not be performed for this or subsequent IF 
experiments due to lack of available cells. Sample AML1 showed the largest 
increase in number of foci per cell in the CD34- compartment in response to Ara-C 
(p=0.009), in parallel with the largest fold increase of γH2AX by FACS (Figure 
5.6A). Most AML samples showed evidence of an increase in DNA damage, with 
sample AML4 as usual showing no response. Samples AML1, AML3 and AML6 
also showed differences in DNA damage between CD34+ and CD34- populations, 
showing heterogeneous responses within samples. 
 
Again overall it can be seen that each AML sample displays a differential response 
to Ara-C when analysing DNA damage.  





Figure 5.7 γH2AX foci counts post Ara-C treatment in AML patient samples in 
vivo.  
(A) Representative immunofluorescence staining of γH2AX foci (green) and DNA (blue) 
in CD34+ and CD34- populations of engrafted primary AML patient in vivo, 24 hours 
post final Ara-C treatment. Scale bar, 10 µm. (B) Quantification of the number of foci 
per nuclei represented as frequency of cells with either 0, 1-4 or >4 foci per cell. 100 
cells were counted per condition. **p<0.005, ****p<0.0001 (n=3). Error bars are ± S.D. 
(n=3-6 mice). 
 




5.2.6 DNA repair post Ara-C treatment in vivo. 
 As performed previously, analysis of activation of DNA repair pathways in 
response to Ara-C in primary AML samples was done by the quantification of 
localisation of nuclear foci by IF.  
 
Figure 5.8 53BP1 foci counts post Ara-C treatment in AML patient samples in 
vivo for analysis of NHEJ repair.  
(A) Representative immunofluorescence staining of 53BP1 foci (green) and DNA (blue) 
in CD34+ and CD34- populations of engrafted primary AML patient in vivo, 24 hours 
post final Ara-C treatment. Scale bar, 10 µm. (B) Quantification of the number of foci 
per nuclei represented as frequency of cells with either 0, 1-4 or >4 foci per cell. 100 
cells were counted per condition. ****p<0.0001. Error bars are ± S.D. (n=3-6 mice). 




Observation of 53BP1 nuclear foci for the activation of NHEJ repair was done for all 
AML samples post Ara-C treatment (Figure 5.8A). Comparing between patients it 
can be seen that sample AML1 is the only sample with significant increases in 
frequency of cells with 53BP1 foci after Ara-C treatment, however mild increases in 
foci counts could be seen in samples AML2 and AML4 (Figure 5.8B).  
 
Comparison of CD34+ and CD34- populations in sample AML1 showed that the 
CD34- compartment had constitutively localised foci in up to 80% of cells, which did 
not change upon Ara-C treatment. As well sample AML2 showed a higher 
frequency of CD34- cells with 53BP1 than compared to the CD34+ population. 
Overall in the majority of samples there was an apparent basal level of 53BP1 foci 
in approximately 10-30% of all cells.  
 
Analysis of RAD51 foci localisation for the activation of HR repair was preformed in 
parallel (Figure 5.9A). Across all the samples, except for AML1, there was barely 
evidence of RAD51 foci formation (Figure 5.9B). 50% of CD34+ cells of patient 
sample AML1 showed evidence of HR repair in response to Ara-C treatment, with 
significant increases seen as well in the CD34- compartment of frequency of cells 
with1-4 foci per cell.  
 
In conclusion it would appear that generally the AML patient samples activate 
NHEJ repair within a small frequency of cells, in both the CD34+ and CD34- 
populations in response to Ara-C treatment. 





Figure 5.9 RAD51 foci counts post Ara-C treatment in AML patient samples in 
vivo for analysis of HR repair.  
(A) Representative immunofluorescence staining of RAD51 foci (green) and DNA 
(blue) in CD34+ and CD34- populations of engrafted primary AML patient in vivo, 24 
hours post final Ara-C treatment. Scale bar, 10 µm. (B) Quantification of the number of 
foci per nuclei represented as frequency of cells with either 0, 1-4 or >4 foci per cell. 
100 cells were counted per condition. **p<0.005. Error bars are ± S.D. (n=3-6 mice). 
5.2.7 Gene expression profiling of key DNA damage response and repair 
components. 
As described in the literature there are frequently aberrations of epigenetic 
modulators in AML such as DNMT3a and EZH2, causing changes in gene 




expression (Ernst et al., 2010, Mayle et al., 2015). Although the mutation status of 
such epigenetic regulators is unknown for the samples used in this study, perhaps 
the heterogeneous response shown to Ara-C could be explained by difference in 
expression of DDR effectors. To assess if there were any differences in gene 
expression of different DNA damage and repair components between CD34+ and 
CD34- compartments, an RT2 Profiler PCR array was preformed for the detection 
of specific targets involved in human DNA repair pathways. 
 
Directly after thawing, AML patient samples were sorted by FACS into CD34+ and 
CD34- populations, with the exclusion of any lymphocytic cells expressing CD3 or 
CD19, before RNA extraction. Both CD34+ and CD34- populations for each sample 
were run on the same PCR plate. The samples analysed were unchallenged by 
Ara-C as the aim was to detect any differences in the level of expression of genes 
in the AMLs natural state. 
 
Figure 5.10 Gene expression of DNA damage response components in primary 
AML samples. 
Primary AML samples were sorted into CD34+ and CD34- populations. Gene 
expression was quantified by normalising to housekeeping controls. Data shown is 
relative to the CD34+ population in each individual sample. Data represents one 
experiment with the mean of duplicated samples.  
 
Focusing on genes that are involved in the initial recognition of DNA damage, it 
was clear that sample AML2 had differential expression of ATM, MRE11 and 




RAD50 between CD34+ and CD34- populations (Figure 5.10). MRE11 and RAD50 
code for subunits of the MRN complex, which recognises DSBs and recruits factors, 
such as ATM, to begin co-ordinating a DNA damage response (Uziel et al., 2003).  
 
If a population were to have less of any of these genes they may not be able to 
properly recognise DNA damage. The rest of the patient samples did not have as 
marked differences in gene expressions, however sample AML3 appeared to have 
the opposite result of sample AML2, with relative expression of MRE11 and RAD50 
apparently now less in the CD34- compartment as compared to CD34+ (Figure 
5.10). 
 
Analysis of genes involved in NHEJ repair again highlighted sample AML2 as 
having differential expression between the populations of the genes LIG3 and LIG4 
(Figure 5.11). These genes encode DNA Ligase III and DNA Ligase IV respectively, 
and work to join the DNA back together at the final stage of NHEJ (Lieber, 2010a).  
 
 
Figure 5.11 Gene expression of NHEJ genes in primary AML samples.  
Primary AML samples were sorted into CD34+ and CD34- populations. Gene 
expression was quantified by normalising to housekeeping controls. Data shown is 
relative to the CD34+ population in each individual sample. Data represents one 
experiment with the mean of duplicated samples.  
 
The majority of the samples again have similar expression levels between their 
CD34+ and CD34- compartments in most of the targets analysed. Interestingly 
however, sample AML3 had reduced XRCC5 and XRCC6 expression in their 




CD34- cells compared to CD34+. These genes encode the two subunits for the 
heterodimer Ku70/Ku80 which hold the two ends of the DNA break together during 
NHEJ (Lieber, 2010a). This could suggest that the CD34- population of sample 
AML3 has a less effective NHEJ. 
 
Figure 5.12 Gene expression of HR genes in primary AML samples.  
Primary AML samples were sorted into CD34+ and CD34- populations. Gene 
expression was quantified by normalising to housekeeping controls. Data shown is 
relative to the CD34+ population in each individual sample. Data represents one 
experiment with the mean of duplicated samples.  
 
Finally several genes involved in HR repair were analysed, again with sample 
AML2 and AML3 showing some of the largest differences in expression between 
their CD34+ and CD34- populations. RAD51B, RAD51C, RAD52, BRCA2 and 
XRCC3 all function to ensure the proper recruitment of RAD51, which is the crucial 
catalytic component of HR (Li and Heyer, 2008). A difference in expression of any 
of these components could potentially cause perturbations of HR repair. 
Interestingly the CD34+ population sample AML1 had higher expression of RAD52 
and was the only population to show significant activation of HR in response to Ara-
C. As well, CD34+ AML1 cells had lower expression of BRCA2. RAD52 has been 
shown to be regulate RAD51 in the absence of BRCA2, thus making it a potential 
target for synthetic lethality in the presence of BRCA2 deficiency (Feng et al., 2011).  
Overall it could be suggested that there is differences in the gene expression of 
DNA damage response and repair genes between the LIC containing CD34+ 
populations and the CD34- compartments.  
 





In this chapter the effect of Ara-C on human primary AML samples was determined 
using the in vivo model. The cohort of AML samples were selected based on their 
expression of the CD34 antigen and their ability to engraft into immunodeficient 
mice. As seen in the previous chapter than normal HSPCs and HPCs show 
differential responses to Ara-C both in vivo and in vitro, it was to be determined 
whether the CD34+ LIC containing populations and the CD34- bulk tumour 
compartment responded differently to Ara-C also.  
 
Overall it was shown that CD34+ populations showed the greatest decrease in cell 
number and higher activation of apoptosis in response to Ara-C treatment as 
compared to CD34-, corresponding to what was seen in the HSPC population in 
Chapter 4. In samples AML1 and AML3 this was most apparent with an almost 
complete depletion of human leukaemic cells from the bone marrow, however a 
small CD34- population was still maintained. Sample AML4 showed the least 
reduction in cell numbers and by 7 days there was no significant induction of 
apoptosis in either CD34+ or CD34- populations, suggesting a quick recovery from 
Ara-C treatment. Samples AML2 and AML6 also show quiet rapid recovery of their 
cell numbers, whereas samples AML3 and AML5 continued to even further their 
cell loss in both populations. It is evident to see that Ara-C is indeed an effective 
drug, yet there appears to be subtle differences in sensitivities between samples.  
 
Analysis of cell cycle showed that overall CD34- populations had a higher 
frequency of cells in G0 compared to CD34+, suggesting they had less exposure to 
Ara-C. As CD34- populations do not contain LICs, they correspond to a more 
differentiated population, which would conceivably have more cells in quiescence. 
Thus this would explain the differences in cell numbers post Ara-C treatment 
between the two populations. Interestingly samples AML2 and AML6, the two 
samples that showed recovery of cell numbers 7 days after Ara-C treatment, both 
displayed evidence of enrichment of cells at the G1/S phases, in CD34+ and CD34- 
population. Sample AML4 on the other hand showed no evidence of any changes 
in cell cycle. Whereas samples AML3 and AML5, who showed continual reduction 
in cell number up to 7 days, exhibited huge enrichment of cells within G0, with an 




almost complete abolishment of cells in the cycling phases. It appears that 
differences in reduction of cell number between the two populations could be due 
to the fact that CD34- populations were generally more quiescent. Overall, CD34+ 
and CD34- populations reacted in a similar manner to Ara-C. However AML1 was 
the only sample seeming to go against this trend as the CD34+ compartment 
showed the beginnings of an S-phase block and CD34- cells showed a reduction in 
the cycling phases. Indeed there are evidently differential responses to Ara-C 
between the AML samples when regarding cell cycle status. 
 
This trend of samples AML2 and AML6 reacting in a similar manner was continued 
when they both showed significant increases in DNA damage in the CD34+ 
population in response to Ara-C. AML1 was the only sample that showed the 
CD34- compartment inducing any DNA damage in response to Ara-C. These mild 
inductions of DNA damage were similar to what was seen in vivo for the normal 
haematopoietic cells. When DNA repair was analysed it was evident that there was 
a basal level of NHEJ but the only sample that showed significant activation of 
either NHEJ or HR repair mechanisms in response to Ara-C was sample AML1, 
especially within the CD34+ compartment. Sample AML4, which appeared to be 
the most refractory to Ara-C treatment, showed a small frequency of cells with 
activation of NHEJ, but no HR.  
 
Overall these heterogeneous responses to Ara-C treatment could be due to their 
differences in karyotype. Sample AML1 was the only complex karyotype sample 
with a poor prognosis, yet it was seemingly highly sensitive to Ara-C treatment and 
was one of the only samples to initiate DNA repair mechanisms. Sample AML4 has 
the MLL-AF9 fusion onco-protein, which is also associated with an adverse 
prognosis (Krivtsov and Armstrong, 2007). The expression of the fusion partner 
MLL1 is lost during the translocation and therefore its activity in DNA methylation is 
abrogated causing changes in chromatin structure and gene expression profiles. 
Horton et al. showed that MLL-AF9 enriched for gene signatures in 
chemotherapeutic resistance, which perhaps correlates with sample AML4 
appearing to be the sample most refractory to Ara-C treatment (Horton et al., 2013). 
Samples AML2 and AML3 had normal karyotype associated with an intermediate 
risk, however sample AML3 held a FLT3-ITD mutation which has been shown to 




have a drug-resistance phenotype due to up-regulation of expression of RAD51 
causing enhanced HR repair activity (Seedhouse et al., 2006). Indeed in sample 
AML3 it was shown that the CD34+ population had a higher expression of RAD51 
from analysis by the PCR arrays. However sample AML3 showed only slight 
activation of HR repair in response to Ara-C and was extremely sensitive to 
treatment, with cell numbers and engraftment almost completely diminished, 
seemingly contrary to its expected drug resistant phenotype.  
 
Overall the cohort of AML samples showed heterogeneous responses to Ara-C 
treatment. There were not many apparent differences between the CD34+ and 
CD34- populations apart from an increased amount of quiescent cells, and sample 
AML1 showing a substantial activation of HR. It was again apparent, just like the 
AML cell lines and normal haematopoietic cells, that NHEJ was preferred over HR 
in response to Ara-C induced DNA damage and that there was a basal level of 
activation of NHEJ. Although it cannot be said for certain whether DNA repair 
mechanisms have an effect on the outcome to Ara-C in AML samples, but it can be 
seen that there are differential responses to the DNA damage incurred by Ara-C 
treatment and more investigation into the pathways involved could be key to 
dissecting these responses.  




Chapter 6. Discussion 
This thesis set forth to determine whether differences in DNA repair mechanisms in 
AML patients, compared to normal haematopoietic cells, could be responsible for 
any adverse responses to the chemotherapeutic agent Ara-C. The aim was to 
observe any potential differences in response to Ara-C of CD34+ LIC containing 
compartments and the more differentiated CD34- compartments of AML primary 
samples, as compared to normal haematopoietic stem and progenitor cells. Using 
in vitro and in vivo approaches, responses to Ara-C, focusing on DNA damage and 
repair, were assessed in AML cell lines, UCB cells and primary AML patient 
samples.  
 
It is well established that normal haematopoietic stem and progenitor cell 
populations react inversely to DNA damage, and indeed normal HSPCs appeared 
to show an increased sensitivity compared to HPC when exposed to Ara-C. This 
falls in line with what Milyavsky et al., showed in that in response to irradiation the 
HSC (which in this study they established as CD34+CD38-CD45RA-CD90+) 
displayed greater apoptosis than compared to progenitor cells (Milyavsky et al., 
2010, Yamashita et al., 2015). This mechanism is believed to help maintain the 
integrity of the stem cell pool and protect from DNA damage causing mutations, 
which could cause malignant transformations.  
 
As outlined in Chapter 4 the studies in normal haematopoiesis were performed 
using the UCB model. While this provides a rich source of HSCs, cells from UCB 
represent a young haematopoietic system, which has been shown to differ in the 
DDR compared to the aged haematopoietic system (Rossi et al., 2007, Beerman et 
al., 2014). However, while cells from adult bone marrow (BM) samples would be a 
more age-appropriate model for this study, due to the expense and scarcity of 
available adult BM, UCB is often used in studies of human HSC biology.  
 
For the studies in leukaemia, AML cell lines provided a good starting point as they 
displayed varying sensitivities to Ara-C treatment, while all receiving similar 
amounts of DNA damage in vitro. However, AML cell lines don’t present with much 
phenotypic heterogeneity, unlike primary AML samples, so different populations 




within the cell lines could not be analysed against the CD34+ CB HPC and HSPC 
populations.  
 
The analyses on primary AML samples were performed in vivo using CD34 
expressing samples, with diverse karyotypes, comparing their CD34+ LIC 
containing and CD34- tumour populations. While it initially seemed that the CD34+ 
populations were more sensitive to Ara-C treatment, based on cell counts and 
activation of apoptosis, the influence of cell cycle status appeared to be a 
contributing factor to their response.  
 
When examining normal HSPCs and HPCs for their cell cycle statuses post Ara-C 
treatment, differences between the populations were revealed. By the later time 
points of exposure to Ara-C in vitro, most of the HPCs were stalled at the G1/S 
phase, whereas HSPCs showed a G0 enrichment and reduction in the G2/M 
cycling phases. For the HPCs, the same results were reflected in vivo, however 
HSPCs appeared to show no difference in cell cycle status. The AML patient 
samples reacted in a similar manner to Ara-C treatment displaying either a G1/S 
phase accumulation, G0 enrichment or no alteration. While there were no major 
observable differences between CD34+ and CD34- AML populations, within each 
sample in response to Ara-C, it appeared that AML patient samples as a whole 
either reacted like normal HPCs or HSPCs. Assessment of BrdU incorporation 
would add another layer of knowledge onto the cell cycle differences. If added to 
the system at the same time as Ara-C, any cells that have BrdU in their DNA and 
are in G0 at the time of analysis may have been able to preform a full cycle of cell 
division without consequence from Ara-C. 
 
LICs from CD34+ AMLs have been shown to arise from early progenitor 
populations such as LMPP (Goardon et al., 2011b) and also from CD38+ 
progenitors (Taussig et al., 2008, Sarry et al., 2011, Eppert et al., 2011) which may 
include mature GMPs. Therefore, this suggests that perhaps the AML patient 
samples, based on the phenotypic origin of their LIC, may be being influenced in 
their responses to chemotherapy as it can be seen that AML samples either act in 
a HPC like manner, or like HSPCs. 
 




Overall in response to Ara-C AML cell lines, normal CB cells and AML patient 
samples all displayed preferential activation of NHEJ repair over HR repair. Many 
studies observing DNA damage responses in the HSC have utilised ionising 
radiation as the main source of DNA damage. These studies show that due to the 
quiescent nature of the stem cells NHEJ is favoured, however when cells are 
pushed to cycle they induce HR repair (Mohrin et al., 2010, Beerman et al., 2014). 
While NHEJ repair can take place at any point in the cell cycle, HR repair is specific 
to the cycling S/G2/M phases (Sancar et al., 2004). The mode of action of Ara-C 
requires the cell to be within the S-phase of the cell cycle and for DNA to be 
replicating to enforce its effect, therefore it could have been speculated that HR 
should have occurred and not NHEJ repair. 
 
Whilst in vitro there was clear evidence of a proportion of cells activating NHEJ 
repair after Ara-C treatment, disappointingly in vivo this was less evident. As was 
suggested in the discussion of Chapter 4, this may be due to the differences in 
dosage of Ara-C and time points analysed between the models. In vivo, instead of 
analysing cells after the full dose regime had been administered, examination 
following a couple of doses of Ara-C could have feasibly captured any on-going 
DNA damage responses as Ara-C was beginning to take effect. Although the 
seven-day dose regime was perhaps too harsh for the kinetics of DNA damage 
analysis, it helped gain an insight into the landscape post Ara-C of any remaining 
cells.  
 
What is chronically understudied is the effect Ara-C has on normal haematopoietic 
cells within the bone marrow, particularly primitive CD34+ populations. Indeed, Ara-
C would not typically be administered to a healthy patient with a healthy 
haematopoiesis. However, in cases of haematological disease, such as AML or 
lymphoma, there is still a residual normal haematopoietic system that comes into 
contact with the drug. Post induction therapy, with a treatment regime utilising Ara-
C, most patients are able to achieve a remission with the return of a functional 
haematopoietic system. Thus it could be speculated that normal haematopoietic 
cells could be more resilient and evasive to chemotherapy than their malignant 
counterparts. Indeed, this could be due to the highly quiescent phenotype of the 
LT-HSC (Foudi et al., 2009, Bradford et al., 1997, Cheshier et al., 1999), or the 




high expression of drug efflux transporters, known to be active on primitive stem 
populations (McKenzie et al., 2007, Chaudhary and Roninson, 1991, Scharenberg 
et al., 2002). Simply meaning, they potentially have a greater ability to evade the 
action of Ara-C compared to more differentiated cells and thus can remain latent in 
the bone marrow during treatment. As well, these same characteristics have been 
postulated as mechanisms of chemoresistance for the LIC, where the primitive 
malignant cells can remain quiescent and protected before leading to an eventual 
relapse. As with any cancer treatment, analysis of their effect on the normal cells is 
paramount to helping provide more targeted therapies. Therefore, this study helps 
shed some light onto how human CD34+ may behave when coming into contact 
with chemotherapeutic agents. Indeed, as Ara-C is routinely not solely used for 
treatment regimes, assessing the effect of other chemotherapeutic agents used in 
combination with Ara-C, such as daunorubicin and fludarabine would also be 
beneficial.  
 
To further elucidate the mechanisms surrounding the variable cell cycle control 
post Ara-C treatment between the normal stem and progenitor populations and the 
AML patient samples, it would be advantageous to investigate the molecular 
decisions surrounding the response to Ara-C. At the onset of DNA damage there is 
a concerted activation of multiple pathways, all defined under the umbrella of the 
DNA damage response. Cell cycle checkpoints are an important part of this 
process and are intimately linked with DNA repair, therefore analysis of the key 
molecular entities involved in G1 and S phase checkpoints would be beneficial to 
understanding why Ara-C causes G0 enrichment in some AML samples and the 
HSPC populations, yet a apparent G1/S block in other AML samples and HPCs, 
with abolishment of G2/M phases. Examination of the p53/p21 axis could 
potentially be key to unravelling this and how this could lead to downstream 
decisions of initiation of DNA repair mechanisms in response to DNA damage. 
Indeed these molecular queues would shed light on the decisions that carry the cell 
into the preference for NHEJ repair. 
 
Study of DDR mechanisms within normal human HSCs and LICs poses quite the 
challenge, mainly due to the rarity of the populations and therefore shortage of 
material to work with. Indeed, after Ara-C treatment this problem is even more 




exacerbated. DDR mechanisms are primarily controlled by protein-protein 
interactions and phosphorylation events, which often require abundant amounts of 
cells to analyse. Yet the majority of DNA damage studies in human haematopoiesis 
so far have had to rely on genomic and transcriptome approaches due to greater 
reliability and effectiveness with low cell numbers. The targeted PCR array on 
CD34+ and CD34- populations from the panel of AML samples performed in this 
study was one such approach. There was evidence of differential expressions of 
DNA repair genes between LIC and tumour populations of some of the samples, 
however as gene expression signatures can be karyotype dependent, a larger 
cohort of samples would be needed for validation.  
 
While this study focuses on the DNA repair pathways as a possible reason for 
differential responses to Ara-C treatment, resistance to Ara-C is most likely a 
mixture of different contributing factors. Although these works provide evidence of 
activation of DNA repair pathways in response to Ara-C it was hard to conclude 
from this data whether it was a true contributor in the response to Ara-C. After all, 
DNA repair is by no means the full story when assessing the responses to the 
cytotoxic drug. In early studies of chemoresistance to Ara-C much of the focus was 
on how the drug was metabolised and transported in and out of the cell. To first 
transform Ara-C into its active and functional form Ara-CTP, a number of 
phosphorylation steps are needed. The down regulation in the expression of one of 
the key enzymes involved in this process, deoxycytidine kinase (DCK), or presence 
of mutations effecting its activity, have been correlated to a poorer response to Ara-
C in AML patients and in vitro studies (Bhalla et al., 1984, Song et al., 2009, 
Veuger et al., 2000). Or conversely, up regulation of cytidine deaminase (CDA), 
which transforms Ara-C into the inactive Ara-U (uracil arabinoside), again 
correlates with an increased resistance to Ara-C treatment (Schroder et al., 1996). 
Both these mechanisms would contribute to reducing the amount of active Ara-C 
available to incorporate into the DNA thus causing DNA damage. 
 
Another means that by which levels of Ara-C within the cell could be affected to 
contribute to chemoresistance, is by alterations in the influx of the drug by the 
human equalibrative nucleotide transporter hENT1 (Hubeek et al., 2005, Wiley et 
al., 1982), or increased expression of efflux transporters from the ABC family such 




as MRP8 (encoded by ABCC11), which is has particular affinity for Ara-C transport 
(Efferth et al., 2001, Guo et al., 2009). By their very nature, stem cells have a 
higher expression of efflux transporters to protect from damage by toxic agents 
(Scharenberg et al., 2002). Taking this into account it is believed that LIC 
populations may also hold this characteristic, giving them enhanced 
chemoresistance than compared to bulk tumour populations (Wulf et al., 2001, de 
Grouw et al., 2006). However, frustratingly inhibitors of drug transporters have 
preformed poorly with limited success in the clinic for treatment of AML (Peck et al., 
2001, Greenberg et al., 2004, Fisher and Sikic, 1995).  
 
Despite the many associations afforded over the years, which provide evidence for 
different mechanisms contributing to chemoresistance, this study has shown that 
Ara-C is still able to effectively incorporate in DNA and inflict damage, suggesting 
there is still a potential mechanism downstream of Ara-C metabolism and cellular 
transport for chemoresistance. 
 
Stepping back and assessing chemoresistance in AML from a broader perspective 
it can be seen that perhaps one of the biggest challenges facing effective treatment 
of AML is the inherent clonal heterogeneity of the disease and the clonal evolution 
observed during treatment. A key study, using whole genome sequencing to track 
mutations in AML patient samples at diagnosis and relapse, showed that during 
treatment, specific clones may be selected which can arise again after remission to 
cause relapse (Ding et al., 2012). Subsequent work showed that the LIC frequency 
was significantly increased at relapse when compared to matched diagnostic 
samples, as well as showing an overall diverse physiological change to the original 
disease presented (Ho et al., 2016). The subsequent relapsed clone always 
harbours an increased mutational burden, compared to its founding clone at 
diagnosis, and has acquired chemoresistance to the treatments previously used. 
These new mutations observed at relapse are most likely created from the harsh 
cytotoxic treatments used causing DNA damage, and may be providing the 
transformed clones a survival advantage.  
 
To corroborate the clonal dynamics observed in AML patient samples during 
treatment with the work done here, it would be beneficial to compare the 




characteristics of the clones, which are present at diagnosis with the clones that 
persist after Ara-C treatment into relapse. Specifically analysing if there are any 
differences in activity and kinetics of the DNA damage and repair pathways. Indeed 
in this study it is seen that leukaemic cells prefer NHEJ repair in response to Ara-C 
treatment. Therefore one possible outcome could be that a particular subset of 
clones has a higher capacity for DNA repair in response to cytotoxic treatments 
and with the preference for the inaccurate NHEJ repair, this could help generate 
the additional mutations observed at relapse. 
 
How DNA damage and repair mechanisms play a part in adverse responses to 
Ara-C treatment in AML requires further exploration as addressed in this study. As 
well, understanding how normal haematopoietic cells may be affected by the 
chemotherapeutic agent are important in the bigger picture of Ara-C response. 
Ultimately, a collaborative analysis of the molecular mechanisms governing LIC 
and HSC DNA repair, quiescence and drug metabolism may be key to providing 





Chapter 7. Appendix 
7.1 Buffers 
Annexin Binding Buffer 
Supplier: BD Pharmingen 
10 mM HEPES 




300 mM NaOH  
1 mM EDTA 
Make to pH 13 
 
Immunofluorescence Blocking Solution 
10% Normal goat serum  
2% BSA 
0.1% Triton-X100  




2.5 M NaCl 
100 mM EDTA  
10 mM Tris  
10% DMSO 
0.1% Triton-X, 
Make to pH 10 
 
Neutralisation Buffer 
0.4 M Tris  






PBS (Phosphate buffered saline) 
100 mM sodium phosphate 






Antibody Company Clone/Reference Application 
Phospho-histone 
H2A.X (Ser139) 
Cell Signalling 20E3 FACS 
Phospho-histone 
H2A.X (Ser139) 
Millipore JBW301 IF 
Rabbit mAb IgG 
XP™ Isotype 
Control 
Cell Signalling DAE1 FACS 
Alexa Flour® 594 
goat anti-mouse 
IgG 
Molecular Probes A11005 IF 
Alexa Flour® 488 
goat anti-rabbit IgG 
Molecular Probes A11008 IF 
AnnexinV BD Pharmingen BMS306 FACS 
53BP1 Santa Cruz H-300 IF 
RAD51 Santa Cruz H-92 IF 
Ki67 BD Pharmingen B-56 FACS 
IgG1, kappa 
Isotype Control 
BD Pharmingen MOPC-21 IF 
hCD45 eBioscience HI30 FACS 
mCD45 eBioscience 30-F11 FACS 
CD34 BD Pharmingen 8G12 FACS 
CD38 eBioscience HIT2 FACS 
CD45RA eBioscience HI100 FACS 
CD90 eBioscience Ebio5310 FACS 
Lineage Cocktail 1 BD Pharmingen 340546 FACS 
CD19 BD Pharmingen 555415 FACS 
CD33 BD Pharmingen 555450 FACS 
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